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Abstract
Babitha Machireddy
COMPUTATIONAL STUDY TARGETING ANTI-FUNGAL TAVABOROLE
ANALOGS AND ANTI-CANCER BRACO19
2017-2018
Chun Wu, Ph.D.
Master of Science in Pharmaceutical Sciences

This thesis comprises of three computer aided drug design studies utilizing
molecular docking and molecular dynamic simulations: (i) a lead optimization study
virtually screening an initial library of ~120000 lead compounds targeting fungal leucyl
tRNA synthetase, (ii) an exploratory study to understand the binding pathway of
BRACO19 to a parallel telomeric DNA G-quadruplex by MD simulations and compare
with experimentally solved X-ray crystal structure (iii) a comparative study to understand
the lack of selectivity of BRACO19 to various topologies of human telomeric DNA Gquadruplex over DNA duplex.
The first chapter provides the background information required to understand the
molecular docking studies and molecular dynamics simulation (MD) studies conducted and
discussed in this thesis. This introductory chapter is organized as follows: the first section
is an introduction to molecular recognition in protein-ligand interactions, the second
section introduces computer-aided drug design, the third section introduces homology
modelling, the fourth section discusses molecular docking and virtual screening, the fifth
section introduces methods for binding affinity prediction and the sixth section explains
MD simulations.
The second chapter of this thesis proposes a library of compounds with enhanced
activity compared to the parent molecule it had been modified from. Tavaborole, the
v

recently approved topological anti-fungal drug, inhibits leucyl tRNA synthetase by
irreversible covalent bonding and hinders protein synthesis. The benzo-boroxole
pharmacophore of tavaborole is responsible for its unique activity. This study theoretically
proposes molecules with improved anti-fungal affinity.
The third chapter of this thesis explores the binding pathway of anti-cancer drug,
BRACO19 and human telomeric DNA G-quadruplex. G-quadruplex specific ligands that
stabilizes the G-quadruplex, have great potential to be developed as anticancer agents. A
free human telomeric DNA G-quadruplex and an unbound BRACO19 are simulated and
the resulting structure is then compared with an experimentally solved X-ray structure of
human telomeric G-quadruplex with a bound BRACO19 intercalated within the Gquadruplex. Three binding modes have been identified: top end stacking, bottom
intercalation and groove binding. Bottom intercalation mode (51% of the population) is
identical to the binding pose in the X-ray solved crystal structure.
The fourth chapter of this thesis compares different topological folds of human
telomeric DNA G-quadruplexes (parallel, antiparallel and hybrid) that have been
experimentally solved using molecular dynamic simulation to understand the 62-fold
preferential selectivity of BRACO19 towards human telomeric DNA G-quadruplex over
DNA duplex. Groove binding mode was found to be the most stable binding mode for the
duplex and top stacking mode for the G-quadruplexes. The non-existential binding
selectivity of BRACO19 can be accounted to the similar groove binding to both the duplex
and the G-quadruplex. For that reason, a modification should be induced such that this
prospective ligand destabilizes binding to the duplex but stabilizes the G-quadruplex
binding.
vi
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Chapter 1
Introduction to Computer-Aided Drug Design
1.1 Introduction
Based on principles of molecular recognition, computer-aided drug design (CADD)
utilizes the increasing computational power to develop and employ various theoretical
models for drug discovery and design. Over the years, computer-aided drug design
(CADD) demonstrated to be effective and instrumental in influencing drug discovery and
molecular recognition. Even though the fast computational tools are not absolutely accurate
due to the resources, time and manpower required to perform experimental methods to gain
the same insights renders CADD very valuable for drug discovery and design.(Tang, 2010)
The subject of designing drugs with high affinity for specific biological receptors
is of continuing intellectual and practical interest. Molecular simulations and molecular
modelling studies provide insights about the interactions contributing to the association of
biological molecules. Before designing a model that can simulate association or
dissociation of biological molecules, a systematic and exhaustive understanding of
molecular recognition is essential. (Lamb & Jorgensen, 1997) The molecular establishment
of many ubiquitous and crucial biological functions is formed by protein-ligand
interactions. A rational guide to therapeutic drug design is attained by understanding the
qualitative and quantitative components of the physical forces governing the protein-ligand
interactions. Therefore, it is of immense scientific and practical importance to understand
the role of molecular recognition in protein-ligand interactions.
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1.2 Molecular Recognition
Molecular recognition is the non-covalent interactions between two or more
molecules through van der Waals forces, hydrogen bonding, metal coordination and π-π,
hydrophobic, or electrostatic interactions. Molecular recognition mediates interactions
between receptors and ligands, proteins and proteins, nucleic acids and proteins, antigens
and antibodies, enzymes and substrates etc. (Cleaves, 2011) Molecular recognition is
defined by two characteristics: (i) affinity; governed by the strength of non-covalent
interactions and (ii) specificity; relative strength of those non-covalent interactions with
respect to another ligand/receptor. (Demchenko, 2001) Understanding the mechanisms of
protein function is to understand the protein–ligand interactions. Therefore, it is crucial to
understand the characterization and quantification of the energetics that govern the
formation of a protein–ligand complex (Perozzo, Folkers, & Scapozza, 2004).
1.2.1 Affinity and specificity. The change in binding free energy of the complex
compared with other potential targets determine the affinity and specificity of proteinligand interactions. (Tang, 2010) One of the most significant thermodynamic quantities
used to characterize the driving force is Gibbs free (binding) energy (G°). It indicates the
capacity of a thermodynamic system to do maximum or reversible work at isothermal and
isobaric conditions. A protein–ligand–solvent system is considered as a simple solutesolvent thermodynamic system, where the protein and ligand molecules are solutes and
liquid water and buffer ions make a solvent system. Accordingly, thermodynamic laws
dictate the interactions between them, resulting heat transfer and how these energy changes
between the solutes and solvent correlate to association of protein and ligand (Gilson &
Zhou, 2007).
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Change in binding (Gibbs) free energy (∆G°) depends on two independent
thermodynamics entities: change in enthalpy (∆H°) and change in entropy (∆S°) written
as,
∆G° = ∆H° − T∆S° (Pirzadeh, Beaudoin, & Kusalik, 2012)

(1.1)

It should be noted that the free energy (∆G°) is defined merely by the initial and
final thermodynamic states, regardless of the pathway connecting these two states. (Du et
al., 2016)
1.2.1.1 Enthalpy. Enthalpy (∆H°) is the total energy of the system, i.e., the sum of
the internal energies of the solute and solvent and the energy required to solvate the system.
(Li, Xie, Liu, & Liu, 2014) In general, the binding enthalpy of a thermodynamic system is
the change in energy as a consequence of noncovalent interactions formed (van der Waals
forces, hydrogen bonding, metal coordination and π-π, hydrophobic, or electrostatic
interactions) at the binding site. (Perozzo et al., 2004)
1.2.1.2 Entropy. Entropy (∆S°) is the disorder or randomness of atoms and
molecules in the system. The binding entropy (∆S°) (the total entropy change associated
with binding) can be broken down into solvent entropy change (∆SS°), conformational
entropy change (∆SC°) and translational and rotational degrees of freedom lost due to the
formation of protein-ligand complex (∆ST°):
∆S° = ∆SS° + ∆SC° + ∆ST° (Du et al., 2016)

(1.2)

In protein-ligand complex formation, the binding entropy (∆S°) is mostly derived
from solvation, de-solvation and the degrees of freedom of both ligand and protein during
complex formation. When the ligand is transferred from the hydrophilic solvent to the
predominantly hydrophobic binding site, entropy change of the ligand (∆SL) can be split
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into conformational entropy (∆SC°) (accessible rotamers), configurational entropy (∆ST°)
(translational and rotational), and vibrational entropy (∆SV°) as follows,
∆SL°= ∆SC°+ ∆ST°+ ∆SV°

(1.3)

Entropy change of the protein (∆SP) can also be split into the same components as
the ligand. However, under the assumption that the entropy change in the protein is
negligible, essential simplification of the model does not consider entropy change in the
protein (∆SP) when bound to different ligands.
1.2.2 Challenges in entropy estimation. As mentioned in 1.2.1.2 solvation and
de-solvation of both protein and ligand contribute to the entropic changes. Additionally,
multiple binding states, entropy-entropy compensation, and configurational entropy also
contribute to the entropic changes. These entropic changes are both challenging and
energetically critical to accurately model the heuristic methods. Various theoretical
methods were employed to estimate the solvation energies involved in protein-ligand
interactions. Theoretical studies including MD simulations and intrinsic solvent
representation (MM-GBSA, MM-PBSA, etc.) have been developed and applied.
While docking the ligands into the binding site, the flexibility of the same is
ignored. Accounting to this oversimplification to reduce the computational expense,
docking ignores enthalpy-entropy compensation. This compensation, an effect of the
receptor’s assumed rigidity, contributes to inaccurate entropy estimation.
1.3 Homology Modeling
3D structure of a protein can be obtained using X-ray crystallography or NMR
spectroscopy studies are available in the Protein Data Bank (PDB) (Westbrook, Feng,
Chen, Yang, & Berman, 2003), http://www.rcsb.org/pdb. However, when the 3D structure
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of a protein is unknown, a theoretical protein model can be generated based on a
homologous protein with known 3D structure. A technique known as homology modeling
predicts the 3D structure of the protein utilizing its amino-acid sequence and the topology
of the homologous protein (template). (Withana-Gamage, Hegedus, Qiu, & Wanasundara,
2011) This technique is based on the structural similarity of evolutionarily related proteins.
(Chandonia & Brenner, 2005; Vitkup, Melamud, Moult, & Sander, 2001)
Generating a homology model of an amino-acid sequence is a multi-step process:
(i) template identification, (ii) sequence alignments and (iii) model building (Joo, Lee, &
Lee, 2012) (Vyas, Ukawala, Ghate, & Chintha, 2012).
1.4 Protein–Ligand Binding Models
Binding mechanisms of proteins and ligands have been explained by three known
models; the lock-and-key (E.

Fischer, 1894), induced fit (Koshland, 1958) and

conformational selection (Csermely, Palotai, & Nussinov, 2010; Du et al., 2016; Ma,
Kumar, Tsai, & Nussinov, 1999; Tobi & Bahar, 2005; C.-J. Tsai, S. Kumar, B. Ma, & R.
Nussinov, 1999).
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Figure 1. Three protein models; (A) lock-and-key model, (B) induced fit model and (C)
conformation selection model.

1.4.1 The lock-and-key model. The lock-and-key model (Figure1A) employs a
rigid ligand being fit into a rigid binding site of a rigid protein, where the ligand fits into
the binding pocket like a key in a lock. However, this mechanism conflicted the
experimental evidence demonstrated by the protein-ligand complexes whose initial protein
and ligand structures did not resemble the final structure.
1.4.2 The induced fit model. Contrary to the lock-and-key model, the induced fit
model (Figure 1B) employs a flexible binding site in the protein and a conformational
change is induced at the binding pocket by the approaching ligand. This model illustrates
the binding mechanism of the protein-ligand complex demonstrating minor conformational
changes after the ligand binding at the binding site.
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1.4.3 The conformational selection model. One main characteristic assumption in
both induced fit and lock-and-key models is that the protein adopts a singular, stable
conformation throughout the binding process. But, most proteins are inherently dynamic.
And the conformational selection model considers this inherent flexibility.
The conformational selection model (Figure 1C) defines protein with its implicit
flexibility based on the free energy landscape (FEL) theory of protein structure and
dynamics. (Bryngelson, Onuchic, Socci, & Wolynes, 1995; Frauenfelder, Sligar, &
Wolynes, 1991; Henzler-Wildman & Kern, 2007; Miller & Dill, 1997) This model
hypothesizes the protein to be an assembly of conformations existing in equilibrium with
different population distributions. Therefore, an approaching ligand has the opportunity to
choose the most appropriate conformation and shift the equilibrium accordingly.
1.5 Computer-Aided Drug Design
Computer-aided drug design (CADD) is utilized to illustrate the application of
molecular modeling methods and computational chemistry to drug design. Escalation of
computational influence enabled CADD to study more complex biomolecular systems and
to define, develop and apply more physically accurate models.
1.5.1 Motivation. Employing experimental methods such as X-ray crystallography
or NMR solvation techniques to atomically resolve ligand bound complexes at an atomic
level is extremely time-consuming and laborious and therefore limits their applicability in
drug design. With that said and done, virtual docking and in-silico screening provides rapid
and relatively accurate resolution for rationalization and visualization.
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1.5.2 Protein–ligand docking. The most economical and relatively fast
computational tool used for in-silico prediction of binding modes and affinities is
molecular docking (Sousa et al., 2013). In the contemporary drug discovery process,
protein–ligand docking (a sub-category of molecular docking) signifies a particularly
essential methodology. (S.-Y. Huang & Zou, 2010; Manly, Chandrasekhar, Ochterski,
Hammer, & Warfield, 2008; Sousa et al., 2013) Protein-ligand docking is utilized to
virtually-screen large libraries of prospective ligands and identify the lead compounds
(Sergio, Nuno, Pedro, & Maria Joao, 2010). Consequently, over the past 20 years, protein–
ligand docking played an active role in pharmaceutical research. There is a great assortment
of docking software packages available for academic and commercial use. Well-known
among them are AutoDock (G. Jones, Willett, Glen, Leach, & Taylor, 1997; Morris et al.,
2009), DOCK (Ewing, Makino, Skillman, & Kuntz, 2001; S. Mukherjee, Balius, & Rizzo,
2010), FlexX (Rarey, Kramer, Lengauer, & Klebe, 1996), Glide (Friesner et al., 2006) and
GOLD (G. Jones et al., 1997).
There are two essential components in protein–ligand docking: (i) the search
algorithm; searches for good binding poses of the ligand with respect to the receptor in the
binding pocket (ii) the scoring function; estimates the binding affinity of the generated
binding poses, ranks them, and identifies the most favorable binding pose(s) of the ligand
with respect to the receptor in the binding pocket. (Du et al., 2016)
The search algorithms have evolved with the protein-ligand binding mechanisms;
from the completely rigid-body methods to the flexible ligand-rigid protein, and then to the
flexible ligand–flexible protein methods. (Sousa et al., 2013)
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1.5.2.1 Scoring functions. To assess the binding affinity of the ligand towards the
protein, fast and approximate mathematical methods, scoring functions, are used. (Ewing
et al., 2001) Scoring functions render a compromise between speed and accuracy based on
various approximations. Scoring functions are thus particularly suitable for highthroughput tasks, such as molecular docking, virtual screening, library design, and so on.
(Liu & Wang, 2015)
Many scoring functions are available for protein–ligand docking studies. They are
classified into three general classes based on how they were devised: the force-field-based,
the empirical-based, and the knowledge-based scoring functions. (Du et al., 2016)
1.5.2.1.1 Force-field-based scoring functions. The force-field defines the potential
energy of the system. In the force-field-based scoring functions, the binding affinities are
estimated based on force-field parameters (physics-based functions and parameters)
derived from quantum mechanical calculation of non-covalent interactions (N. Huang,
Kalyanaraman, Irwin, & Jacobson, 2006). Including the molecular interactions induced by
binding, changes induced in the solvent and particularly, the entropic effects would give a
more accurately estimated binding affinity. Explicit treatment of water molecules or
utilizing implicit solvent models can justify the solvent effect. Implicit solvent models such
as Poisson–Boltzmann surface area (PB/SA) model (Rocchia et al., 2002; J. Wang, Morin,
Wang, & Kollman, 2001) and the generalized-Born surface area (GB/SA) model. (G. D.
Hawkins, C. J. Cramer, & D. G. Truhlar, 1995; Still, Tempczyk, Hawley, & Hendrickson,
1990)
ΔGBinding =ΔEvdW +ΔEElectrostatic + ΔEH-bond + ΔGDe-solvation
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(1.4)

1.5.2.2 Empirical scoring functions. Empirical scoring functions utilize either
machine learning methods or regression to parameterize the interactions as favorable or
unfavorable (penalty) energy terms. (Eldridge, Murray, Auton, Paolini, & Mee, 1997;
Grinter & Zou, 2014) These energy terms include contributions from hydrophilic contacts,
hydrophobic contacts, electrostatic and van der Waals energies, number of hydrogen
bonds, number of rotatable bonds that are immobilized upon complex formation, or change
in solvent accessible surface area (SASA) upon complex formation (Tang, 2010). PLP, (G.
Verkhivker, Appelt, Freer, & Villafranca, 1995) ChemScore, (Eldridge et al., 1997;
Murray, Auton, & Eldridge, 1998) X-Score, (R. Wang, Lai, & Wang, 2002) and GlideScore
(Friesner et al., 2004; Friesner et al., 2006) are popular examples of empirical scoring
functions.
1.5.2.2.1 Xtra precision glide score. XP Glide docking function employed in this
thesis falls under semi-empirical scoring functions which employs H2O de-solvation
energy terms. It was reported that in XP glide docking, the scoring function reproduced
experimental binding affinities of 198 ligands on various complexes with known
experimental binding affinities. Out of the 198 ligands 132 ligands docked agreeably with
root mean square deviations and average absolute deviations of 1.73 kcal/mol and 1.34
kcal/mol respectively.(Friesner et al., 2006)
Glidescore employed by Glide software is formulated as follows
XP Glidescore = ECoul + EvdW + EBind + EPenalty

(1.5)

EPenalty = EDe-solvation + ELigand-strain (Friesner et al., 2006)

(1.6)
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1.5.2.3 Knowledge-based scoring functions. The knowledge-based scoring
functions assume that the close inter-atomic interactions between the protein and the ligand
occurring more frequently can be energetically favorable than those anticipated by a
random distribution and for that reason, contribute favorably to the binding affinity
(Muegge, 2006). In other words, the statistical potentials are derived from the close
contacts statistically studied in a training set containing suitable samples.
lig prot

A = ∑ ∑ ωij (r)
i

(1.7)

j

Each scoring function has its own pros and cons and none of them are neither
accurate nor generally applicable. Therefore, the idea of using a combination of scores
from multiple scoring functions, consensus scoring strategy, has been introduced to
improve the accuracy and applicability. (Charifson, Corkery, Murcko, & Walters, 1999;
S.-Y. Huang, Grinter, & Zou, 2010; G. M. Verkhivker et al., 2000)
1.5.2.4 Limitations and practical considerations. Most docking methods employ
various limiting assumptions and oversimplifications, such as rigid binding site, inaccurate
solvent representation, random probability distribution functions used in conformational
searches etc. Many virtual screening studies identified a high percentage of false positives
because

of

these

often-necessary

simplifications

and

inherently

inaccurate

implementations. The utility of docking studies conducted to identify novel potent ligands
are limited by the rigid depiction of the ligand binding site (neither side-chain nor backbone
flexibility) as the ligand may bind to the protein by an induced fit mechanism. This
unsophisticated oversimplification is ignoring certain important energetic modifications
induced by potential structural changes usually observed in the ligand binding process.
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Additionally, a rigid-binding site does not account for enthalpy-entropy compensation
(discussed in Section 1.2.2).
In docking, implicit solvent representations are used. Docking methods ignore the
critical role of bound water molecules, accounting to the lack of explicit solvent
representation. This misrepresentation might lead to inaccurate prediction of the binding
pose. In these cases, including explicit waters at the binding site might achieve more
accurate docking predictions. Accurate binding affinity estimations can be achieved by
accurate physical representation of solvation and de-solvation effects.
1.5.3 Binding affinity predictions. One of the most critical and challenging
components to structure-based CADD is predicting binding affinity. (Ajay & Murcko,
1995; Gohlke & Klebe, 2002) Predicting accurate binding affinity is essential to various
applications including identification of native binding mode using molecular docking,
identification of lead compounds by virtual screening of ligand libraries, and increasing
target specificity and enhancing binding affinity for lead optimization. (Kitchen, Decornez,
Furr, & Bajorath, 2004; Lyne, 2002; Shoichet, 2004) Even though first-principle methods
such as free energy perturbation (FEP), (Kollman, 1993) linear interaction energy (LIE),
(Hansson, Marelius, & Åqvist, 1998) and MM-PBSA/GBSA (P. A. Kollman et al., 2000)
have gone through significant developments to predict accurate binding affinity (Beveridge
& DiCapua, 1989; Hansson et al., 1998; P. A. Kollman et al., 2000), fast and relatively
accurate empirical scoring functions are still widely used in drug discovery. (Böhm &
Stahl, 2003)

12

1.5.3.1 Free energy calculations. Principles of statistical thermodynamics are
utilized in protein-ligand binding free energy calculations. These are extensive
computational simulations (Molecular Dynamics or Monte Carlo) based calculations and
require computational efforts of higher magnitude by several orders than the traditional
scoring functions. As a reward for the highly intensive computation, the results of free
energy calculations ought to be reliable and almost quantitative.
The free energy calculations carry an advantage over the faster scoring functions
by including both the energetic (solvation energy and potential energy) and entropic
(solvent effects and flexibility/dynamics of both protein and ligand) contributions. And the
free energy calculations do not require case-by-case parameter fitting. (de Ruiter &
Oostenbrink, 2011; S. Thomas & Andreas, 2010)
The three main types of free energy calculations: the alchemical calculation, the
path sampling, and the endpoint methods. Many factors like the length of the simulation,
whether the absolute or relative binding free energy was calculated and whether an implicit
or explicit solvent was used would affect the efficiency and accuracy of the calculations.

Figure 2. Endpoint methods.
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1.5.3.1.1 Endpoint methods. The endpoint method calculates the binding free
energies of the unbound state and bound state only. The intermediates stages are not
considered. It is to be noted that endpoint method could be the efficient method of all three.
The most endpoint methods applied to the binding free energy calculations, are molecular
mechanics generalized Born surface area (MM-GBSA) and molecular mechanics PoissonBoltzmann surface area (MM-PBSA). (P. A. Kollman et al., 2000; Srinivasan, Cheatham,
Cieplak, Kollman, & Case, 1998) In the GB/SA and PB/SA method, the binding free
energy is calculated as:
∆GBind = GC – (GP+GL)

(1.4)

Where GC is the free energy of the protein-ligand complex’s molecular system, GP
is the free energy of the protein molecular system and GL is the free energy of the ligand
molecular system. (Joseph M. Hayes, 2012) The free energy of each system is defined as:
G = EMM + GSolv – TS

(1.5)

Where EMM is the total molecular mechanics energy of molecular system in the gas
phase, GSolv is a solvation free energy of the molecular system in solvent and T is
temperature and S is the entropy of the molecular system (Joseph M. Hayes, 2012) (as
explained in section 1.2.1.2). The total molecular mechanics energy of molecular system
is defined as the sum total of energies contributed by covalent interactions (EBonded),
electrostatic interactions (EElec) and van der Waals interactions (EVdW). (Joseph M. Hayes,
2012)
EMM = EBonded + EElec + EVdW

(1.6)

The molecular mechanics energy of the system is computed by the molecular
mechanics energy function known as force field. The solvation free energy constitutes
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polar (GGB/PB) and non-polar (GSASA) contributions from the solvent. (Joseph M. Hayes,
2012)
GSolv = GGB/PB + GSASA

(1.7)

The polar component is interpreted by the generalized Born (GB)/Poisson or
Poisson-Boltzmann (PB) model. The non-polar component is considered to be proportional
to solvent-accessible surface area (SASA). (Joseph M. Hayes, 2012)
GB/SA and PB/SA methods are more relevant to ranking of ligand binding
affinities rather than to predict absolute binding free energies owing to its intrinsic
approximations. Although, incorporating solute entropy (Foloppe & Hubbard, 2006) and
solvent effects (Singh & Warshel, 2010) in binding affinity calculations is challenging,
many studies applied PB/SA and GB/SA methods successfully and have generated some
promising results. (Joseph M. Hayes, 2012) As MM-GBSA calculation ranges between
their intermediate position between the empirical scoring and rigorous alchemical
calculation methods in terms of both accuracy and computational intensity, PB/SA and
GB/SA methods could be useful for post-processing of the docked structures or be used to
rationalize the observed differences. (Genheden & Ryde, 2015)
1.5.3.1.2 Limitations and practical considerations. Although empirical scoring
functions came a long way, there is still room for significant improvement in both
applicability and accuracy. Accurate ranking of binding poses based on the relative
affinities is still a challenge. The inability of the scoring functions used in virtual-screening
studies to characterize the accurate binding nature constitutes as another limitation,
especially the unrepresented systems of the training sets. Considering a best-case scenario
where the docking method successfully predicted an accurate binding pose, the rigidity of
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the protein might hinder the accuracy of the scoring function and generate false positives
and false negatives. Under the assumption of correct binding pose prediction, this
limitation could be circumvented by estimating binding affinities by utilizing first-principle
methods.
1.6 Molecular Dynamics Simulations
As mentioned in section 1.5.2.4 the rigidity of protein is a limitation to the CADD
and needs to be dealt with. However, to deal with this and develop a computational
technique that can simulate protein dynamics, highly complicated and computationally
demanding quantum-mechanics (QM) based calculations pertaining large molecular
systems are required.
Molecular dynamics (MD) simulations, first developed in the late 1970’s
(McCammon, Gelin, & Karplus, 1977), simulate atomic motions utilizing Newtonian
physics based on unassuming approximations thereby reducing the computational
intricacy.
Initially, NMR spectroscopic, X-ray crystallographic, or homology-modeling data,
in that preferential order, is utilized to formulate a molecular model of the molecular
system. A potential energy estimation is made by formulating the forces acting on every
atom of the system (Cornell et al., 1995). In short, covalent and non-covalent interactions
of the system. Simple virtual springs, were utilized to model chemical bonds; sinusoidal
function that approximates the energy differences between eclipsed and staggered
conformations was utilized to model dihedral angles and atomic angles. The Lennard-Jones
6- 12 potential (J. E. Jones, 1924) was utilized to model van der Waals interactions and
Coulomb’s law for electrostatic interactions. These energetic terms need to be
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parameterized to fit QM calculations and experimental data to be able to simulate the
natural dynamics of the molecules. All these parameters are collectively known as a ‘forcefield’. Because these parameters define the forces that control and effect the dynamics
simulation. Commonly known MD simulation force-fields are AMBER (Cornell et al.,
1995; J. Wang, R. M. Wolf, J. W. Caldwell, P. A. Kollman, & D. A. Case, 2004),
CHARMM (Brooks et al., 1983), GROMOS (Christen et al., 2005) , NAMD (Kale et al.,
1999; Phillips et al., 2005) etc. They differ only in the approach of parameterization.
Once the force-field has been defined, all atoms of the system are stimulated
according to Newton’s laws of motion. The molecular system will be simulated often by
only 1-2 quadrillionths of a second, and this process is repeated, typically for a million
times. As it is apparent that MD simulations require so many calculations, computer
clusters or super-computers utilizing multiple processors in parallel are used to conduct
them. One of the applications of MD simulations is validation of a force-field by comparing
simulated data with experimental data (van Gunsteren, Dolenc, & Mark, 2008).
Many properties such as the time evolved root-mean-squared coordinate deviation
(RMSD) to the initial structure, distance time series, angle time series, energy time series,
H-bond time series etc., are used to characterize these MD simulation trajectories.
However, extracting and evaluating some properties such as entropies and enthalpies can
be time-consuming. Moreover, interpretation of these properties and the intrinsic
relationships between the molecular configurations could be lost in the complexity of the
data. To simplify this complexity a data mining tool called clustering analysis is used.
(Karpen, Tobias, & Brooks, 1993; Shao, Tanner, Thompson, & Cheatham, 2007; Shenkin
& McDonald, 1994) Clustering analysis groups MD simulated conformations based on
17

homogenous structures. (Barnard & Downs, 1992) Every conformation is divided into
various groups known as clusters based on relative similarity. Each cluster has MD
simulated conformations that resemble each other or are distinct from every other cluster.
(Hartigan & Wong, 1979)
Regardless of the flaws in conformational sampling and current force fields, the
insights offered by MD simulations into protein dynamics play essential roles in CADD.
In the drug-binding process, the small molecule (drug) does not find a distinct rigid
structure, rather a large dynamic molecular system in constant motion. MD simulations
succeed where NMR, X-ray crystallography, and homology modeling generated rigidreceptor models fail to reproduce the dynamic molecular recognition and drug binding
processes. Whether it’s a lock-key model, where the drug might bind to a rigid binding
pocket and the receptor dynamics are limited (E. Fischer, 1894) or a more common
induced-fit model, where the drug binds only to a handful of conformations sampled by its
dynamic receptor (Kumar, Ma, Tsai, Wolfson, & Nussinov, 1999; Ma et al., 1999; Ma,
Shatsky, Wolfson, & Nussinov, 2002; C. J. Tsai, S. Kumar, B. Ma, & R. Nussinov, 1999)
or it’s inducing more conformational changes that cannot be sampled in its absence
(Koshland, 1958), dynamics of the receptor play a crucial role in drug-binding process.
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Chapter 2
CADD in Boron Therapeutics
2.1 Abstract
Tavaborole, the recently approved topological anti-fungal drug, inhibits leucyl
tRNA synthetase by bonding covalently and hinders protein synthesis. The benzo-boroxole
pharmacophore of tavaborole is responsible for its unique activity. With proper
understanding of the tavaborole binding site, designing a molecule to enhance the binding
affinity of tavaborole analogs should be quite achievable. The 3D crystal structure of fungal
leucyl tRNA synthetase has not been solved yet. So, a theoretical 3D model of fungal leucyl
tRNA synthetase has been generated and a combinatorial library has been generated by
optimizing libraries of already synthesized drugs designed based on biological activity of
amino-benzo-boroxoles on anti-cancer cell lines using the previously generated 3D model.
The synthesized drug library mimics the activity of bortezomib. However, the
pharmacophore benzo-boroxole would be more relevant to tavaborole rather than to
bortezomib with a boronic acid pharmacophore. This study theoretically proposes
molecules with prospective improved affinity towards fungal leucyl tRNA synthetase. To
improve the selectivity of these molecules a theoretical 3D model of human leucyl tRNA
synthetase has been generated and the hits from fungal leucyl tRNA synthetase are
analyzed at the human leucyl tRNA binding site.
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2.2 Introduction
The element boron is not very commonly found in living bodies however, it has
been gaining a lot of attention recently, accounting to its potential for new therapeutic
biological activity and drug design. The attention may be new but utilization of boron
containing compounds started long ago with boric acid and borax.(Tibi, 2006) Although
boron-chemistry started with inorganic boric acid compounds and borax, it has now
progressed to boron based organic chemistry (Baker et al., 2009; Baker, Tomsho, &
Benkovic, 2011; Das et al., 2013; Hernandez et al., 2013) and has been approved as an
anticancer (bortezomib (Adams et al., 1998)) and antifungal (tavaborole (Leśnikowski,
2016; Rock et al., 2007)) agents in 2003 and 2014 respectively.
2.3 Tavaborole
Tavaborole (5-fluoro-1,3-dihydro-1-2,1-benzoxaborole/AN2690) is one of the
most effective treatment against onychomycosis. Tavaborole is a topically acting, broadspectrum antifungal agent. (Baker et al., 2006; A. K. Gupta & Simpson, 2012)
2.3.1 Onychomycosis. A fungal infection of the nail plate or the nail bed is known
as onychomycosis. (Seebacher et al., 2007; J. Thomas et al., 2010) 80-90% of the
documented onychomycosis cases are assessed to be caused by the dermatophytes
Trichophyton rubrum and Trichophyton mentagrophytes. (J. Thomas et al., 2010) When
left untreated, the nail plate gradually deteriorates and separates from the nail bed. It has
been reported that the incidence rate of onychomycosis is ∼10% of the worldwide
population, ∼20% for the >60 years old population and ∼50% for people aged >70 years.
(Elewski, 2000; J. Thomas et al., 2010; Westerberg & Voyack, 2013) While
onychomycosis is not life threatening, it can lead to the cause of lesions in other regions
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and can have grave consequences in combination with various other conditions like
diabetes and contribute to poor quality of life. (Drake et al., 1999; A. P. Gupta, Verma, &
Ikram, 2000) There is always a chance of infecting others and becoming a public health
hazard.
2.3.2 Mechanism of action. The mechanism of action of the fungicidal tavaborole
has been explained by crystallographic, biochemical, and chemical studies. Tavaborole has
been demonstrated to be effective against Trichophyton rubrum and Trichophyton
mentagrophytes by targeting their leucyl tRNA synthetase (LeuRS). (Adamczyk-Woźniak,
Komarovska-Porokhnyavets, Misterkiewicz, Novikov, & Sporzyński, 2012; Baker et al.,
2006; Rock et al., 2007) LeuRS belongs to the class of aminoacyl-tRNA synthetases, a
class of enzymes crucial for protein synthesis.
2.4 Hypothesis
Pathi et al., reported cell viability assays for synthesized amino-benzo-boroxoles
(tavaborole analogs) and in-vitro IC50 for compounds with promising anti-cancer activity
(Suman, Patel, Kasibotla, Solano, & Jonnalagadda, 2015) mimicking boronic acid
containing bortezomib and ixazomib. However, the pharmacophore, benzo-boroxole is
more similar to tavaborole. So, the goal of this study is to optimize anti-fungal activity of
tavaborole analogs reported in table 1. This study attempts to optimize the antifungal
activity of these molecules by modifying them and identify lead compounds by virtual
screening.
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Table 1
Biological activity of benzo-boroxoles in anticancer cell-lines.
MIA PaCa-2
MDA-MB-231
Structure
% Cell Viability
% Cell Viability
IC50
50 µM 12.5 µM
50 µM 12.5 µM
28.6

28.2

61.0

83.0

17.5

22.4

8.3

2.7

44.8

44.3

123.2

118.7

53.9

63.0

IC50

11.5

11.9

2.5 Role of LeuRS in Protein Synthesis
Major steps of protein synthesis are initiation, elongation, termination and folding.
Amino-acylation reaction triggers the protein synthesis, followed by elongation of protein
chain by formation of several peptide bonds and elongating the protein. The elongation is
then terminated by the termination codon of mRNA and the newly synthesized protein is
released which is consequently folded into its tertiary structure. (Banik & Nandi, 2013)
2.5.1 Amino-acylation reaction. The amino-acylation reaction binds an aminoacid with the transfer RNA. These amino-acids are attached to the transfer RNA (tRNA)
by a class of enzymes called aminoacyl tRNA synthetases. The tRNA then transfers those
amino acids onto the protein. (Ibba & Söll, 2000) There are two classes of aminoacyl tRNA
synthetases. The difference between the classes being the transfer of the amino acid onto
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2’-hydroxyl group in class I and onto 3’-hydroxyl group in class II. Most cells have at least
20 different aminoacyl tRNA synthetases, one for each essential amino acid. (Khan et al.,
2011) However, many cells have additional aminoacyl tRNA synthetases. LeuRS belongs
class II of the aminoacyl tRNA synthetases.
The aminoacylation of tRNA is a 2-step process: (i) the formation of aminoacyl
adenylate from the amino acid in question triggers the 2nd step. The 𝛼-carboxylate group
of the amino acid and the 𝛼-phosphate group of ATP forms aminoacyl adenylate, a mixed
anhydride, in the presence of divalent magnesium (Mg2+) ions and releases pyrophosphate.
This pyrophosphate is further hydrolyzed and the equilibrium shifts forward. (Figure 3)

Figure 3. Step 1 of amino-acylation.

(ii) The amino acid in aminoacyl adenylate is transferred onto the 2′ or 3′ sugar
hydroxyl group of the 3′-terminal adenosine nucleotide of the tRNA. (Figure 4) The
accuracy of this process is very essential in ensuring the fidelity of the genetic code which
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would otherwise lead to the synthesis of nonsensical proteins (Hong et al., 1996). To
ensure this accuracy, most of the aminoacyl tRNA synthetases have an editing site to rectify
an incorrectly aminoacylated tRNA (Schimmel & Schmidt, 1995). LeuRS has same
proofreading mechanism. The synthetic and editing domains of LeuRS are separated by
more than 30 Å (Cusack, Yaremchuk, & Tukalo, 2000; Fukunaga & Yokoyama, 2005).

Figure 4. Step 2 of amino-acylation.

Many factors affect the selectivity for amino-acids; including amino-acid size,
shape along with presence of an editing domain. (Guo & Schimmel, 2013) Concluding that
aminoacyl tRNA synthetases are crucial for protein synthesis and cellular viability.
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2.6 Tavaborole and LeuRS

Figure 5. Inhibition of leucylation due to the formation of boronic ester

Tavaborole selectively binds to the editing domain of LeuRS. Tavaborole slowly
and strongly binds to the binding site of leucine and renders the whole protein useless.
(Figure 5) This subsequently stops protein synthesis or leads to synthesis of proteins with
incorrect amino acid sequence. Eventually leading to apoptosis one way or the other.
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(Lincecum et al., 2003) Rock et al reported that based on the X-ray crystallographic studies
on LeuRS of Thermus thermophiles complexed with tavaborole, a tRNA-tavaborole spiroester adduct was formed by sp2 hybridized boron from the boroxole ring and the two 2’,
3’-hydroxyl groups on the terminal adenosine where boron is sp3 hybridized with
tetrahedral structure. The two hydroxyl groups which are essential to the amino-acylation
reaction. This adduct formation is further stabilized by two H-bonds with threonine peptide
and H2O molecule. (Rock et al., 2007) This process is commonly referred to as the
oxaborole tRNA trapping (OBORT) mechanism. (Baker et al., 2011) This stable complex
has a half-life of ~7 hours at the active site. (Rock et al., 2007)
2.6.1 Structure-activity relationships (SAR) of benzo-boroxoles. Based on the
SAR studies the 5-membered boroxole ring in which the boronic acid is embedded is
critical for the therapeutic activity of the benzo-boroxoles. Comparative biochemical
assays indicated substantial loss of antifungal activity with 6-membered ring and acyclic
boronic acids analogs. (Rock et al., 2007)

Figure 6. Structure of Tavaborole.
This unusual activity of the boroxole ring is fascinating, since the reaction
coefficient of the very well-known boric, boronic and borinic ester formation with alcohols
in aqueous solution by the corresponding acid is pKa dependent not the structure.
(Martínez-Aguirre, Villamil-Ramos, Guerrero-Alvarez, & Yatsimirsky, 2013) Benzo-
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boroxoles certainly have more pKa than acyclic boronic acids. (Yamaguchi et al., 2012)
This however, cannot be correlated with disproportional increase of antifungal activity
when compared with their corresponding acyclic boronic acids. Although in the absence
of LeuRS, both benzo-boroxoles and acyclic boronic acids promptly forms esters
interchangeably in neutral aqueous medium with mono-alcoholic and di-alcoholic
compounds due to their obviously low association constants. (Martínez-Aguirre et al.,
2013; Tomsho & Benkovic, 2012) Therefore, it is presumed that the hydrolysis of the
boronic ester that usually occurs in the aqueous solution is prevented by the hydrophobic
binding site of the editing domain in LeuRS. Thus the benzo-boroxole-LeuRS complex is
selectively stabilized. (Baker et al., 2006)
2.7 Computational Approach
The goal of the study is to suggest modifications to the given library so as to
optimize the fungicidal activity. The approach would be to
(i)

validate the protein and ligand model,

(ii)

virtually dock the ligands at the binding site and analyze the corresponding

interactions,
(iii)

identify the modification site,

(iv)

enumerate the fragment library at individual modification sites and rank the

fragments with respect to the fragment site,
(v)

enumerate fragments at all sites and score the final modifications.
2.7.1 Challenges and assumptions. As mentioned in section 2.1.1.1 80-90% of

onychomycosis is caused by Trichophyton mentagrophytes and Trichophyton rubrum.
However, the 3D structure of LeuRS of neither is available in the protein data bank.
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2.7.1.1 Homology modeling. A theoretical 3D structure of the Trichophyton
rubrum has been generated by Prime (Jacobson, Friesner, Xiang, & Honig, 2002; Jacobson
et al., 2004) (Schrodinger) software utilizing its amino-acid sequence from UniProt
Consortium© (Magrane & Consortium, 2011) and the template, PDB ID: 2V0G from PDB
(Berman et al., 2000). 2V0G is the 3D structure of LeuRS from Thermus Thermophilus, a
Gram negative eubacterium, complexed with tRNA and characterizing formation of spiroester adduct of tavaborole with the ribose of adenosine- 76 at the editing site of the LeuRS.

Figure 7. 3D representation of homology modeled fungal LeuRS complexed with tRNA
non-covalently interacting with tavaborole.

The Glide (Friesner et al., 2004; Friesner et al., 2006; Halgren et al., 2004) software
utilized to do molecular docking can form one covalent bond (covalent docking (Zhu et al.,
2014)) with the amino-acid residues but the software has not been developed to conduct
two subsequent covalent bonds formation with nucleic acids as observed with the spiroester formation.
To overcome this challenge only the approachability of the ligand is studied. As the
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covalent bond formation is a fast and exothermic reaction which facilitates subsequent
covalent bonds. The only challenge is approaching the binding site.

Figure 8. tRNA - Tavaborole complex adjusted from covalently bonded complex to noncovalently interacting moieties.

2.8 Comparison with Human LeuRS – Selectivity
Tavaborole is a topologically acting drug. Systemic activity can be induced when
the ligands have preferential activity towards fungal LeuRS rather than human LeuRS.
With this goal, the binding sites of both fungal and human LeuRS with tavaborole are
modelled and compared.
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Figure 9. 3D representation of superimposed structures of homology modeled fungal and
human LeuRS complexed with tRNA non-covalently interacting with tavaborole.

As mentioned in section 2.1.1.3 the SAR studies suggest the binding site of the
fungal LeuRS and tavaborole to be hydrophobic. This is explained by comparison of the
amino-acids interacting at the binding sites of both fungal and human LeuRS.

Table 2
Homology, identity and similarity statistics of human LeuRS compared to fungal LeuRS.
Human LeuRS
Homology
45 %
Identity
34 %
Similarity
46 %

Figure 10. Sequence alignment of fungal LeuRS and human LeuRS; residues interacting
with tavaborole at the binding site of fungal LeuRS are depicted in yellow and human
LeuRS in blue. Residues depicted in green are common in both fungal and human LeuRStavaborole binding site.
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The highlighted cells in the table 3 indicate amino-acids that might be responsible
for high hydrophobicity at the binding site of tavaborole with fungal LeuRS compared to
the human LeuRS.

Table 3
List of the interacting residues (highlighted in figure 10) at the binding site of fungal LeuRS
compared with residues interacting at the binding site of human LeuRS; highlighted cells
indicate residues that might be responsible for high hydrophobicity of tavaborole binding
site in fungal LeuRS.
Fungal
Human
VAL
VAL
VAL

LYS

GLU

GLU

ALA

LEU

PRO

MET

SER

GLU

ILE

LEU

GLY

GLY

VAL

VAL

GLN
LEU
ALA
GLN

PRO

LYS

LYS

ASP

GLU

LEU

LYS

ALA

ILE

TYR

TYR
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2.9 Methods
2.9.1 Inherent inaccuracies in experimental data. As mentioned in section
2.6.1.1 a theoretical 3D structure of LeuRS of Trichophyton rubrum has been generated by
homology modeling using the template, PDB ID: 2V0G from PDB (Berman et al., 2000).
The Protein Data Bank (PDB) has a comprehensive collection of X-ray and NMR solved
biomolecular structures. (Westbrook et al., 2003) However, the experimental conditions
like pH, temperature, salt concentrations etc., induced to crystallize the protein might differ
from the actual physiological conditions. The minimal resolution of the model might result
in inaccuracies on an atomic level. (Tang, 2010) For these reasons, this structure needs to
be prepared to increase the accuracy and structural correctness of the 3D protein model.
Schrodinger Maestro’s protein preparation wizard was used to prepare the structure,
optimize the H-bond network and minimize the potential energy of the protein model.
("Maestro© 2014 Schrödinger, LLC. Manuals,")
2.9.2 Validation. The protein-ligand model, 3D structure generated from
homology modelling in complex with tavaborole, was validated by conducting molecular
docking studies on compounds with reported inhibitory activity against cytoplasmic LeuRS
of Saccharomyces cerevisiae S288c (Rock et al., 2007).
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Table 4
List of IC50 values of compounds structurally similar to tavaborole and their corresponding
docking scores and MM-GBSA values against fungal LeuRS. The highlighted cells depicts
activity of tavaborole.
Structure

IC50

Target Name

Docking score

MM-GBSA

>100000 nM

Leucyl-tRNA
synthetase,
cytoplasmic

-4.348

-48.626

>100000 nM

Leucyl-tRNA
synthetase,
cytoplasmic

-4.728

-43.9

>100000 nM

Leucyl-tRNA
synthetase,
cytoplasmic

-4.515

-46.239

=2100 nM

Leucyl-tRNA
synthetase,
cytoplasmic

-3.19

-56.181

>100000 nM

Leucyl-tRNA
synthetase,
cytoplasmic

-3.86

-52.873

Docking score vs RTlog(IC50)

-RTlog(IC50)

4
3.5
3

R² = 0.7287

2.5
2
3

3.5

4
-Docking scores

4.5

5

Figure 11. Graph plotting Docking score of the molecules listed in table 4 vs binding
experimental binding affinity of the same.
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MMGBSA vs RTlog(IC50)

-RTlog(IC50)

4
3.5
R² = 0.5543

3
2.5
2
40

45

50
- MMGBSA

55

60

Figure 12. Graph plotting MM-GBSA values of the molecules listed in table 4 vs binding
experimental binding affinity of the same.

The XP docking score generated by Glide and MM-GBSA free binding energy
generated by Prime are used to validate the binding affinities. The docking score of the
active compound is lowest when compared with other structurally similar compounds
(indicated in Figure 6) however, the MM-GBSA binding energies show that the active
compound has highest binding affinity when compared with the same (indicated in Figure
7). So, MM-GBSA free binding energy is used to validate the relative affinity of the
ligands.
2.9.3 Screening the given library. The given libraries are screened based on the
binding pose; extra precision glide docking is used to generate a binding pose for each
ligand. The generated binding pose is then compared by super imposing with the binding
pose of tavaborole. The ligands with binding poses that does not facilitate the formation of
the spiro-adduct (boronic ester) are screened out. Since covalent bond formation between
the boroxole of the ligands and the di-hydroxyl groups of the ribose from tRNA is essential
for the spiro-adduct formation, the ligand binding pose that does not super impose its
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boroxole with the boroxole of tavaborole is eliminated.
2.9.3.1 Ligand library 1 (LL1). In the tables 5, 6 and 7 listed below the
highlighted cells have structures that successfully reproduced the binding pose that
facilitates the covalent bond formation between boron and the ribose of adenosine of the
tRNA.

Table 5
List of the docked molecules of ligand library 1 (LL1) and their binding pose in complex
with fungal LeuRS. The highlighted cells indicate molecules with appropriate binding pose.
LL1_1
Binding Pose

LL1_2

Binding Pose

LL1_3

Binding Pose
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Table 5 (continued)
LL1_5

Binding Pose

LL1_6

Binding Pose

LL1_7

Binding Pose

LL1_8

Binding Pose

LL1_9

Binding Pose
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Table 5 (continued)
LL1_10

Binding Pose

LL1_12

Binding Pose

LL1_13

Binding Pose

LL1_14

Binding Pose
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2.9.3.2 Ligand library 2 (LL2).

Table 6
List of the docked molecules of ligand library 2 (LL2) and their binding pose in complex
with fungal LeuRS. The highlighted cells indicate molecules with appropriate binding pose.
LL2_1

Binding Pose

LL2_2

Binding Pose

LL2_3

Binding Pose

LL2_4

Binding Pose
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Table 6 (continued)
LL2_5

Binding Pose

LL2_6

Binding Pose

2.9.3.3 Ligand library 3 (LL3).

Table 7
List of the docked molecules of ligand library 3 (LL3) and their binding pose in complex
with fungal LeuRS. The highlighted cells indicate molecules with appropriate binding pose.
LL3_1
Binding Pose
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Table 7 (continued)
LL3_2

Binding Pose

LL3_3

Binding Pose

LL3_4

Binding Pose

LL3_5

Binding Pose
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Table 7 (continued)
LL3_6

Binding Pose

LL3_7

Binding Pose

LL3_8

Binding Pose

LL3_9

Binding Pose

LL3_10

Binding Pose

41

2.9.4 Binding site analysis and enumeration. The binding site analysis provided
by maestro is used to analyze and define prospective R-group positions to optimize the
non-covalent interactions without disrupting the covalent bond formation. This binding site
analysis indicates voids in the protein-ligand complex at the binding site. (i) Defining an
R-group at each of these voids would optimize the affinity of the ligand without disrupting
the covalent bond formation. Once these sites have been identified, (ii) the fragment library
provided by maestro is used to enumerate R-groups at those defined positions. (iii) The
resulting ligand library is docked into the binding site. (iv) The resulting docked binding
poses are screened based on their comparability with binding pose of tavaborole. (v) Free
energy binding affinities of these screened molecules (MM-GBSA ∆GBind) are calculated.
5 best fragments with high affinity binding poses are selected. After filtering out top
affinity generating fragments at all predefined R-group sites, (vi) these fragments are then
enumerated at their respective enumeration site. (vii) Once the generated library is docked
and the incomparable binding poses are filtered out, a final active ligand library is
generated. (viii) MM-GBSA ∆GBind is then calculated for this final ligand library.
To achieve selectivity over human LeuRS, (ix) this final ligand library is docked
into the binding site of the human LeuRS-tavaborole complex, which has been homology
modelled using the same template used for generating fungal LeuRS-tavaborole complex.
(x) Then a maximum of six best ligands displaying major affinity difference between
fungal and human LeuRS and obviously favorable towards fungal LeuRS are screened.
(Listed in results (2.9.5) section for every active ligand listed in tables 5, 6 and 7. For those
ligands which gave no positive hits against human LeuRS, 6 best ligands with high MMGBSA ∆Gbind are listed.)
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2.9.5 Results.
2.9.5.1 Modifications on LL1_5. As mentioned in section 2.3.2 (i) Table 8
depicts the surfaces generated by binding site analysis and the voids represented by these
surfaces. And these voids can accommodate a new R-group that optimize the affinity
without disrupting the binding pose. All the prospective sites for modification are
depicted in figure 13.

Table 8
The surfaces generated by binding site analysis at the LeuRS-LL1_5 binding site and
arrows point to modification site of R0, R1, R2, R3 and R4.
R0
R1
R2, R3 and R4

Figure 13. 2D structure of LL1_5 illustrating all the prospective modification sites.

Once the modification sites have been identified, these sites have been enumerated
with fragment library provided by Schrodinger followed by steps (iii), (iv) and (v) (listed

43

in 2.9.4 section). The best fragments for ligand LL1_5 are listed in tables 9, 10, 11, 12 and
13.

Table 9
Hits from single site enumeration at R0 of LL1_5.
Structure

MM-GBSA ∆GBind

-86.14

-87.13

-81.23

-81.85
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Table 10
Hits from single site enumeration at R1 of LL1_5.
Structure

MM-GBSA ∆GBind

-72.67

-78.85

-75.09

-91.14

-93.29
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Table 11
Hits from single site enumeration at R2 of LL1_5.
Structure

MM-GBSA ∆GBind
-78.40

Table 12
Hits from single site enumeration at R3 of LL1_5.
Structure

MM-GBSA ∆GBind
-79.17

-78.49

-99.07

-72.56

-74.74

-75.16
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Table 13
Hits from single site enumeration at R4 of LL1_5.
Structure

MM-GBSA ∆GBind

-83.84

-80.39

Once the top fragments have been identified, the steps (vii) (viii) (ix) and (x) (as listed in
section 2.9.4) are carried out and the final hits are listed below
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Structure

-26.77

-49.19

-67.85

-42.9

-89.48

-85.83

Human

Fungal

-18.66

-59.06

-46.59

Difference

MM-GBSA ∆GBind

-4.707

-8.386

-8.718

Fungal

Hits from enumeration at all modification sites of LL1_5 and comparison with human LeuRS.

Table 14

-5.497

-8.105

-5.51

Human

0.79

-0.281

-3.208

Difference

Docking Score
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Structure

Table 14 (continued)
Docking Score

-57.11

-54.67

-64.02

-57.09

-64.65

-67.48

-9.34

-7.54

-10.4

-4.103

-4.979

-6.485

-6.108

-5.325

-7.741

2.005

0.346

1.256

Fungal Human Difference Fungal Human Difference

MM-GBSA ∆GBind

2.9.5.2 LL1_6.

Table 15
The surfaces generated by binding site analysis at the LeuRS-LL1_6 binding site and
arrows point to modification site of R0, R1, R2, and R3.
R0
R1
R2
R3

Figure 14. 2D structure of LL1_6 illustrating all the prospective modification sites.

Table 16
Hits from single site enumeration at R0 of LL1_6.
Structure

MM-GBSA ∆GBind

-77.07
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Table 17
Hits from single site enumeration at R1 of LL1_6.
Structure

MM-GBSA ∆GBind

-64.97

-69.83

-72.02

-71.15

-64.96

-77.18
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Table 17 (continued)
MM-GBSA ∆GBind

Structure

-73.77

-63.06

-74.05

-80.13
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Table 18
Hits from single site enumeration at R2 of LL1_6.
Structure

MM-GBSA ∆GBind

-63.67

-86.56

-79.08

-71.17

-81.34

-83.17

-68.28
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Table 18 (continued)
MM-GBSA ∆GBind

Structure

-68.01

-78.39

-63.59

-69.64

-67.78

-66.16
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Table 18 (continued)
MM-GBSA ∆GBind

Structure

-74.72

-63.98

-63.94

-65.77

-76.74
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56

Structure

Docking Score

-27.17

-65.76

-74.55

-56.41

-76.58

-95.53

-8.79

-49.4

-39.12

-6.009 -7.339

-5.179 -3.221

-9.908 -7.785

1.33

-1.958

-2.123

Fungal Human Difference Fungal Human Difference

MM-GBSA ∆GBind

Hits from enumeration at all modification sites of LL1_6 and comparison with human LeuRS.

Table 19
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Structure

Table 19 (continued)

-66.68

-42.45

-24.23

-4.538

-4.336

-5.517

-5.057

0.979

0.721

-10.86

-67.96

-57.1

Human Difference Fungal Human Difference

Docking Score

Fungal

MM-GBSA ∆GBind

2.9.5.3 LL1_7.

Table 20
The surfaces generated by binding site analysis at the LeuRS-LL1_7 binding site and
arrows point to modification site of R0, R1 and R2.
R0
R1 and R2

Figure 15. 2D structure of LL1_7 illustrating all the prospective modification sites.

Table 21
Hits from single site enumeration at R0 of LL1_7.
Structure

MM-GBSA ∆GBind

-62.33

58

Table 21 (continued)
MM-GBSA ∆GBind

Structure

-65.10

-73.06

-63.99

-87.76

-72.13

59

Table 21 (continued)
MM-GBSA ∆GBind

Structure

-74.76

-61.71

-28.98

Table 22
Hits from single site enumeration at R1 of LL1_7.
Structure

MM-GBSA ∆GBind
-62.69
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Table 22 (continued)
MM-GBSA ∆GBind

Structure

-80.19

-62.75

-62.41

-61.52

-61.23

Table 23
Hits from single site enumeration at R2 of LL1_7.
Structure

MM-GBSA ∆GBind

-62.77
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Table 23 (continued)
MM-GBSA ∆GBind

Structure

-68.73

-63.95

-84.85

-64.40

-60.05

-61.39
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Table 24
Hits from enumeration at all modification sites of LL1_7.
Structure
MM-GBSA ∆GBind
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Docking score

-117.821

-4.312

-116.719

-3.972

-115.106

-6.325

Table 24 (continued)
Structure

MM-GBSA ∆GBind

Docking score

-113.406

-4.537

-109.529

-6.998

-101.104

-5.017
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2.9.5.4 LL1_9.

Table 25
The surfaces generated by binding site analysis at the LeuRS-LL1_9 binding site and
arrows point to modification site of R0, R1, R2 and R3.
R0 and R1
R2 and R3

Figure 16. 2D structure of LL1_9 illustrating all the prospective modification sites.

Table 26
Hits from single site enumeration at R0 of LL1_9.
Structure

MM-GBSA ∆GBind

-113.32
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Table 26 (continued)

-96.72

-90.34

-98.52

-96.99

-101.01
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Table 27
Hits from single site enumeration at R1 of LL1_9.
Structure

MM-GBSA ∆GBind

-94.43

-86.27

-86.71

-99.59

-105.43

67

Table 27 (continued)
MM-GBSA ∆GBind

Structure

-90.19

Table 28
Hits from single site enumeration at R2 of LL1_9.
Structure

MM-GBSA ∆GBind

-91.07

-88.80

-87.26

68

Table 28 (continued)
MM-GBSA ∆GBind

Structure

-86.28

Table 29
Hits from single site enumeration at R3 of LL1_9.
Structure

MM-GBSA ∆GBind

-84.51

-90.28

-99.97

69

Table 29 (continued)
MM-GBSA ∆GBind

Structure

-91.22

-91.56

-86.53

-93.29

70

Table 29 (continued)
MM-GBSA ∆GBind

Structure

-93.51

-98.35

-93.34

-113.36

-106.35

71

72

-66.53

-50.92

-85.86

-75.93

-94.1

-100.05

-34.94

-27.57

-24.12

-5.228

-7.567

-7.401

-4.823

-9.586

-9.476

-0.405

2.019

2.075

Hits from enumeration at all modification sites of LL1_9 and comparison with human LeuRS.
MM-GBSA ∆GBind
Docking Score
Structure
Fungal Human Difference Fungal Human Difference

Table 30

73

Table 30 (continued)

Structure

Docking Score

-69.2

-60.36

-78.39

-71.54

-84

-84.46

-18.03

-14.8

-12.91

-8.122

-9.217

-5.789

-8.472

-7.919

-7.402

0.35

-1.298

1.613

Fungal Human Difference Fungal Human Difference

MM-GBSA ∆GBind

2.9.5.5 LL1_10.

Table 31
The surfaces generated by binding site analysis at the LeuRS-LL1_10 binding site and
arrows point to modification site of R1 and 2D structure of LL1_10 illustrating its
prospective modification sites.
R1

Table 32
Hits from single site enumeration at R1 of LL1_10 and comparison with human LeuRS.
MM-GBSA ∆GBind
Docking Score
Structure
Fungal Human Difference Fungal Human Diff
-84.665 -38.779

-45.886

-5.589

-4.29

-1.299

-83.961 -34.274

-49.687

-5.264

-4.651

-0.613

-77.476 -30.159

-47.317

-5.114

-5.536

0.422

74

Table 32 (continued)

Structure

MM-GBSA ∆GBind
Fungal Human
Diff

Docking Score
Fungal Human Diff

-77.14

-52.87

-4.594

-5.939

1.345

-68.825 -25.042 -43.783

-4.469

-4.427

-0.042

-67.991 -25.829 -42.162

-4.226

-3.67

-0.556

-24.27

75

2.9.5.6 LL1_12.

Table 33
The surfaces generated by binding site analysis at the LeuRS-LL1_12 binding site and
arrows point to modification site of R0, R1 and R2.
R0 and R1
R2

Figure 17. 2D structure of LL1_12 illustrating all the prospective modification sites.

Table 34
Hits from single site enumeration at R0 of LL1_12.
Structure

MM-GBSA ∆GBind

-64.78

-57.30

76

Table 35
Hits from single site enumeration at R1 of LL1_12.
Structure

MM-GBSA ∆GBind

-79.07

-76.12

-82.66

-87.53

-76.32

-76.82

77

Table 35 (continued)
MM-GBSA ∆GBind

Structure

-80.02

-78.16

-76.98

-72.87

Table 36
Hits from single site enumeration at R2 of LL1_12.
Structure

MM-GBSA ∆GBind

-83.15

78

Table 36 (continued)
MM-GBSA ∆GBind

Structure

-84.46

-77.90

-84.41

-94.13

-91.39

-83.35

79

Table 36 (continued)
MM-GBSA ∆GBind

Structure

-77.10

-75.77

-76.07

Table 37
Hits from enumeration at all modification sites of LL1_12.
Structure
MM-GBSA ∆GBind Docking Score

80

-66.025

-8.314

-65.823

-6.706

Table 37 (continued)
Structure

81

MM-GBSA
∆GBind

Docking
Score

-65.038

-7.699

-64.912

-8.272

-63.531

-7.143

-62.649

-4.704

2.9.5.7 LL1_13.

Table 38
The surfaces generated by binding site analysis at the LeuRS-LL1_13 binding site and
arrows point to modification site of R0, R1, R2 and R3.
R0
R1
R2
R3

Figure 18. 2D structure of LL1_13 illustrating all the prospective modification sites.

Table 39
Hits from single site enumeration at R1 of LL1_13.
Structure

MM-GBSA ∆GBind

-106.41

82

Table 39 (continued)
MM-GBSA ∆GBind

Structure

-85.77

-81.84

-88.51

-85.98

83

Table 39 (continued)
MM-GBSA ∆GBind

Structure

-83.05

-88.55

-93.76

-86.65

84

Table 39 (continued)
MM-GBSA ∆GBind

Structure

-87.43

-83.09

-101.24

-80.49

85

Table 40
Hits from single site enumeration at R2 of LL1_13.
Structure

MM-GBSA ∆GBind

-89.58

-76.07

-91.40

-88.51

86

Table 40 (continued)
MM-GBSA ∆GBind

Structure

-75.18

-76.62

-84.52

-88.24

87

Table 40 (continued)
MM-GBSA ∆GBind

Structure

-79.80

-76.37

-92.66

-83.70

88

89

Structure

Docking Score

-69.61

-63.05

-79.52

-80.35

-81.07

-82

-16.48

-11.46

-1.65

-4.693

-7.962

-5.041

-6.972

-9.069

-7.28

2.279

1.107

2.239

Fungal Human Difference Fungal Human Difference

MM-GBSA ∆GBind

Hits from enumeration at all modification sites of LL1_13 and comparison with human LeuRS.

Table 41

90

Structure

Table 41 (continued)

-76.18

-64.74

-11.44

-4.751

-4.889

-5.794

-6.416

1.043

1.527

-70.14

-79.43

-9.29

Human Difference Fungal Human Difference

Docking Score

Fungal

MM-GBSA ∆GBind

2.9.5.8 LL1_14.

Table 42
The surfaces generated by binding site analysis at the LeuRS-LL1_14 binding site and
arrows point to modification site of R0 and R1.
R0
R1

Figure 19. 2D structure of LL1_14 illustrating all the prospective modification sites.

Table 43
Hits from single site enumeration at R1 of LL1_14.
Structure
MM-GBSA ∆GBind

91

Docking score

-99.76

-7.363

-92.273

-7.616

Table 43 (continued)
Structure

92

MM-GBSA ∆GBind

Docking score

-90.439

-8.352

-89.443

-7.57

-89.001

-7.891

-88.878

-5.312

2.9.5.9 LL2_ 1.

Table 44
The surfaces generated by binding site analysis at the LeuRS-LL2_1 binding site and
arrows point to modification site of R0, R1, R2, R3, R4 and R5.
R0
R1, R2
R3, R4 and R5

Figure 20. 2D structure of LL2_1 illustrating all the prospective modification sites.

Table 45
Hits from single site enumeration at R0 of LL2_1.
Structure

MM-GBSA ∆GBind

-104.90

-103.07

93

Table 45 (continued)
MM-GBSA ∆GBind

Structure

-104.48

-100.39

Table 46
Hits from single site enumeration at R1 of LL2_1.
Structure

MM-GBSA ∆GBind

-95.04

-99.37

-84.04

-86.52

94

Table 47
Hits from single site enumeration at R2 of LL2_1.
Structure

MM-GBSA ∆GBind

-92.71

-88.10

-96.72

Table 48
Hits from single site enumeration at R3 of LL2_1.
Structure

MM-GBSA ∆GBind

-103.72

-97.12

-107.19

95

Table 49
Hits from single site enumeration at R4 of LL2_1.
Structure

MM-GBSA ∆GBind
-98.14

-98.92

Table 50
Hits from single site enumeration at R5 of LL2_1.
Structure

MM-GBSA ∆GBind
-84.05

-81.70

96

97

Structure

-47.39

-41.12

-108.73

-106.04

-74.41

-122.15

-64.92

-61.34

-47.74

Human Difference

Fungal

MM-GBSA ∆GBind

-10.023

-9.422

-8.916

Fungal

-6.56

-7.543

-7.238

-3.464

-1.879

-1.678

Human Difference

Docking Score

Hits from enumeration at all modification sites of LL2_1 and comparison with human LeuRS.

Table 51

98

Structure

Table 51 (continued)

-46.5

-15.67

-91.83

-76.56

-60.88

-45.33

-5.346

-7.242

-5.908

-4.496

-7.213

-4.461

-0.85

-0.029

-1.447

-15.03

-100.73

-85.7

Human Difference Fungal Human Difference

Docking Score

Fungal

MM-GBSA ∆GBind

2.9.5.10 LL2_2.

Table 52
The surfaces generated by binding site analysis at the LeuRS-LL2_2 binding site and
arrows point to modification site of R0, R1, R2 and R3.
R0
R1, R2 and R3

Figure 21. 2D structure of LL2_2 illustrating all the prospective modification sites.

Table 53
Hits from single site enumeration at R0 of LL2_2.
Structure

MM-GBSA ∆GBind

-101.86

99

Table 53 (continued)
MM-GBSA ∆GBind

Structure

-102.86

-104.17

-118.17

-106.42

-107.17

-112.48

100

Table 53 (continued)
MM-GBSA ∆GBind

Structure

-104.67

Table 54
Hits from single site enumeration at R1 of LL2_2.
Structure

MM-GBSA ∆GBind

-104.59

-106.08

-102.93

101

Table 54 (continued)
MM-GBSA ∆GBind

Structure

-104.49

-97.09

Table 55
Hits from single site enumeration at R2 of LL2_2.
Structure

MM-GBSA ∆GBind

-86.42

-82.09

102

Table 55 (continued)
MM-GBSA ∆GBind

Structure

-91.10

-72.06

-84.49

Table 56
Hits from single site enumeration at R3 of LL2_2.
Structure

MM-GBSA ∆GBind

-91.36

-90.75

103

Table 56 (continued)
MM-GBSA ∆GBind

Structure

-94.73

-105.95

104

105

Structure

-71.36

-70.02

-94.19

-112.74

-133.89

-100.76

Human

Fungal

Docking Score

-24.16

-29.4

-21.16

-6.012

-7.603

-8.154

-7.301

-8.437

-5.973

1.289

0.834

-2.181

Difference Fungal Human Difference

MM-GBSA ∆GBind

Hits from enumeration at all modification sites of LL2_2 and comparison with human LeuRS.

Table 57

106

Table 57 (continued)

Structure

-52.08

-70.99

-87.09

-85.51

-14.53

-35.01

-6.193

-6.774

-6.002

-6.124

0.581

-4.067

0.524

Human Difference

Docking Score

-10.069

-5.6

-19.83

-93.13

-73.3

Human Difference Fungal

Fungal

MM-GBSA ∆GBind

2.9.5.11 LL2_3.

Table 58
The surfaces generated by binding site analysis at the LeuRS-LL2_3 binding site and
arrows point to modification site of R0, R1, R2, R3, R4 and R5.
R0
R1, R2, R3, R4 and R5

Figure 22. 2D structure of LL2_3 illustrating all the prospective modification sites.

Table 59
Hits from single site enumeration at R0 of LL2_3.
Structure

MM-GBSA∆GBind

-88.83

-94.16

107

Table 59 (continued)
Structure

MM-GBSA∆GBind

-93.02

-93.97

-92.53

Table 60
Hits from single site enumeration at R1 of LL2_3.
Structure

MM-GBSA ∆GBind

-76.29

Table 61
Hits from single site enumeration at R2 of LL2_3.
Structure

MM-GBSA ∆GBind
-71.98

108

Table 61 (continued)
Structure

MM-GBSA∆GBind

-71.17

-70.06

Table 62
Hits from single site enumeration at R3 of LL2_3.
Structure

MM-GBSA ∆GBind

-88.66

-88.94

-91.37

-92.47

109

Table 62 (continued)
MM-GBSA ∆GBind

Structure

-102.30

-93.91

Table 63
Hits from single site enumeration at R4 of LL2_3.
Structure

MM-GBSA ∆GBind

-89.52

-94.02

-87.92

-90.91

110

111

Structure

Docking Score

-38.94

-15.58

-68.05 -52.47

-1.46

-79.88 -40.94

-94.25 -92.79

-6.25

-7.605 -8.164

-9.587

-4.946 -8.785

0.559

-3.337

3.839

Fungal Human Difference Fungal Human Difference

MM-GBSA ∆GBind

Hits from enumeration at all modification sites of LL2_3 and comparison with human LeuRS.

Table 64

2.9.5.12 LL2_4.

Table 65
The surfaces generated by binding site analysis at the LeuRS-LL2_4 binding site and
arrows point to modification site of R0, R1, R2, R3 and R4.
R0
R1 and R2
R3 and R4

Figure 23. 2D structure of LL2_4 illustrating all the prospective modification sites.

Table 66
Hits from single site enumeration at R0 of LL2_4.
Structure

MM-GBSA ∆GBind

-102.98

112

Table 66 (continued)
MM-GBSA ∆GBind

Structure

-103.72

-94.68

-98.42

Table 67
Hits from single site enumeration at R1 of LL2_4.
Structure

MM-GBSA ∆GBind

-91.12

-89.21

113

Table 67 (continued)
MM-GBSA ∆GBind

Structure

-87.33

-86.63

Table 68
Hits from single site enumeration at R2 of LL2_4.
Structure

MM-GBSA ∆GBind

-93.28

-95.30

-103.54

114

Table 68 (continued)
MM-GBSA ∆GBind

Structure

-95.73

Table 69
Hits from single site enumeration at R3 of LL2_4.
Structure

MM-GBSA ∆GBind

-94.93

-97.01

-96.14

-108.11

115

Table 70
Hits from single site enumeration at R4 of LL2_4.
Structure

MM-GBSA ∆GBind

-76.79

-73.48

116

117

Structure

-39.34

-53.6

-115.1

-86.57

-115.46

-117.77

-61.5

-76.12

-31.2

-6.555

-9.943

-9.666

-6.421

-7.298

-7.197

-0.134

-2.645

-2.469

MM-GBSA ∆GBind
Docking Score
Fungal Human Difference Fungal Human Difference

Hits from enumeration at all modification sites of LL2_4 and comparison with human LeuRS.

Table 71

118

Table 71 (continued)

Structure

-52.67

-50.59

-100.51

-99.78

-49.19

-47.85

-10.286

-7.786

-9.602

-53.34

-103.24

-49.9

Human Difference Fungal

-8.138

-5.209

-6.017

-2.148

-2.577

-3.585

Human Difference

Docking Score

Fungal

MM-GBSA ∆GBind

2.9.5.13 LL2_6.

Table 72
The surfaces generated by binding site analysis at the LeuRS-LL2_6 binding site and
arrows point to modification site of R0, R1, R2, R3, R4, R5, R6 and R7.
R0
R1, R2 and R3
R4, R5, R6 and R7

Figure 24. 2D structure of LL2_6 illustrating all the prospective modification sites.

Table 73
Hits from single site enumeration at R0 of LL2_6.
Structure

MM-GBSA ∆GBind

-71.54

119

Table 73 (continued)
MM-GBSA ∆GBind

Structure

-77.73

-76.81

-83.20

-72.03

Table 74
Hits from single site enumeration at R2 of LL2_6.
Structure

MM-GBSA ∆GBind

-72.63

120

Table 74 (continued)
MM-GBSA ∆GBind

Structure

-90.37

-83.51

-75.85

-99.39

-74.21

-75.28

121

Table 75
Hits from single site enumeration at R3 of LL2_6.
Structure

MM-GBSA ∆GBind

-85.83

-72.36

-79.76

Table 76
Hits from single site enumeration at R4 of LL2_6.
Structure

MM-GBSA ∆GBind

-76.97

122

Table 76 (continued)
MM-GBSA ∆GBind

Structure

-83.40

-72.18

-83.23

Table 77
Hits from single site enumeration at R6 of LL2_6.
Structure

MM-GBSA ∆GBind

-74.13

-67.79

123

124

Structure

Docking Score

-72.23

-70.38

-72.85

-50.07

-83.94

-88.15

-2.47

-11.71

-38.08

-5.292

-9.159

-6.012

-7.55

-8.112

-7.596

2.258

-1.047

1.584

Fungal Human Difference Fungal Human Difference

MM-GBSA ∆GBind

Hits from enumeration at all modification sites of LL2_6 and comparison with human LeuRS.

Table 78

2.9.5.14 LL3_4.

Table 79
The surfaces generated by binding site analysis at the LeuRS-LL3_4 binding site and
arrows point to modification site of R1, R2, R3, R4 and R5.
R1
R2
R3 and R4
R5

Figure 25. 2D structure of LL3_4 illustrating all the prospective modification sites.

Table 80
Hits from single site enumeration at R1 of LL3_4.
Structure

MM-GBSA ∆GBind

-54.01

125

Table 80 (continued)
MM-GBSA ∆GBind

Structure

-72.46

Table 81
Hits from single site enumeration at R2 of LL3_4.
Structure

MM-GBSA ∆GBind

-69.64

-106.00

126

Table 82
Hits from single site enumeration at R3 of LL3_4.
Structure

MM-GBSA ∆GBind

-69.86

-76.06

Table 83
Hits from single site enumeration at R4 of LL3_4.
Structure

MM-GBSA ∆GBind

-60.50

-91.22

-79.08

-74.02

127

Table 83 (continued)
MM-GBSA ∆GBind

Structure

-112.13

-70.44

Table 84
Hits from single site enumeration at R5 of LL3_4.
Structure

MM-GBSA ∆GBind

-68.06

Table 85
Hits from enumeration at all modification sites of LL3_4.
Structure

128

MM-GBSA ∆GBind

Docking
score

-104.593

-10.997

Table 85 (continued)
Structure

129

MM-GBSA ∆GBind

Docking score

-102.667

-8.022

-94.382

-6.692

-87.388

-8.358

-86.375

-10.729

Table 85 (continued)
Structure

130

MM-GBSA ∆GBind

Docking score

-81.409

-8.276

2.9.5.15 LL3_5.

Table 86
The surfaces generated by binding site analysis at the LeuRS-LL3_5 binding site and
arrows point to modification site of R1, R2, R3, R4, R5 and R6.
R1 R2 and R5
R3
R4
R6

Figure 26. 2D structure of LL3_5 illustrating all the prospective modification sites.

Table 87
Hits from single site enumeration at R1 of LL3_5.
Structure

MM-GBSA ∆GBind

-75.77

131

Table 87 (continued)
MM-GBSA ∆GBind

Structure

-84.14

-88.56

Table 88
Hits from single site enumeration at R2 of LL3_5.
Structure

MM-GBSA ∆GBind

-73.57

-72.40

-70.88

Table 89
132

Hits from single site enumeration at R3 of LL3_5.
Structure

MM-GBSA ∆GBind

-67.53

-65.46

-60.40

Table 90
Hits from single site enumeration at R4 of LL3_5.
Structure

MM-GBSA ∆GBind

-90.68

-77.73

133

Table 91
Hits from single site enumeration at R5 of LL3_5.
Structure

MM-GBSA ∆GBind

-73.12

-84.29

-72.97

134

Table 92
Hits from single site enumeration at R6 of LL3_5.
Structure

MM-GBSA ∆GBind

-94.28

-80.17

-90.77

Table 93
Hits from enumeration at all modification sites of LL3_5.
Structure

135

MM-GBSA ∆GBind

Docking
score

-99.802

-11.367

Table 93 (continued)
Structure

136

MM-GBSA ∆GBind

Docking
score

-92.449

-6.889

-90.937

-6.307

-90.255

-7.82

-88.603

-8.928

Table 93 (continued)
Structure

137

MM-GBSA ∆GBind

Docking
score

-88.418

-9.65

2.9.5.16 LL3_6.

Table 94
The surfaces generated by binding site analysis at the LeuRS-LL3_6 binding site and
arrows point to modification site of R1, R2, R3, R4, R5, R6, and R7.
R1
R2 and R3
R4 and R5
R6 and R7

Figure 27. 2D structure of LL3_6 illustrating all the prospective modification sites.

Table 95
Hits from single site enumeration at R1 of LL3_6.
Structure

MM-GBSA ∆GBind

-73.37

138

Table 95 (continued)
MM-GBSA ∆GBind

Structure

-72.51

-75.01

Table 96
Hits from single site enumeration at R2 of LL3_6.
Structure

MM-GBSA ∆GBind

-69.48

-77.17

139

Table 97
Hits from single site enumeration at R3 of LL3_6.
Structure

MM-GBSA ∆GBind

-72.40

-73.00

Table 98
Hits from single site enumeration at R4 of LL3_6.
Structure

MM-GBSA ∆GBind

-69.97

-63.59

140

Table 99
Hits from single site enumeration at R5 of LL3_6.
Structure

MM-GBSA ∆GBind

-78.42

-82.01

Table 100
Hits from single site enumeration at R6 of LL3_6.
Structure

MM-GBSA ∆GBind

-78.45

-67.57

141

Table 101
Hits from single site enumeration at R7 of LL3_6.
Structure

MM-GBSA ∆GBind

-74.60

-69.35

Table 102
Hits from enumeration at all modification sites of LL3_6.
Structure

142

MM-GBSA
∆GBind

Docking
score

-87.245

-9.053

-82.812

-4.707

Table 102 (continued)
Structure

143

MM-GBSA
∆GBind

Docking
score

-82.475

-6.543

-82.203

-10.462

-80.186

-11.144

Table 102 (continued)
Structure

144

MM-GBSA
∆GBind

Docking
score

-77.346

-5.635

2.9.5.17 LL3_9.

Table 103
The surfaces generated by binding site analysis at the LeuRS-LL3_9 binding site and
arrows point to modification site of R1, R2, R3, R4 and R5.
R1
R2
R3, R4, and R5

Figure 28. 2D structure of LL3_9 illustrating all the prospective modification sites.

Table 104
Hits from single site enumeration at R1 of LL3_9.
Structure

MM-GBSA ∆GBind

-69.20
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Table 104 (continued)
MM-GBSA ∆GBind

Structure

-69.27

-74.13

Table 105
Hits from single site enumeration at R2 of LL3_9.
Structure

MM-GBSA ∆GBind

-71.32

-77.16

-69.44
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Table 105 (continued)
MM-GBSA ∆GBind

Structure

-101.38

Table 106
Hits from single site enumeration at R3 of LL3_9.
Structure

MM-GBSA ∆GBind

-64.91

-67.21

Table 107
Hits from single site enumeration at R4 of LL3_9.
Structure

MM-GBSA ∆GBind

-65.45
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Table 107(continued)
MM-GBSA ∆GBind

Structure

-91.55

-90.82

-81.91

Table 108
Hits from single site enumeration at R5 of LL3_9.
Structure

MM-GBSA ∆GBind

-61.94

-62.581
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Table 108 (continued)
MM-GBSA ∆GBind

Structure

-64.493

-61.884

-70.463

-67.986

Table 109
Hits from enumeration at all modification sites of LL3_9.
Structure

149

MM-GBSA ∆GBind

Docking
score

-148.153

-10.79

Table 109 (continued)
Structure

150

MM-GBSA ∆GBind

Docking
score

-114.819

-6.665

-112.359

-7.908

-111.764

-6.42

-107.239

-4.223

Table 109 (continued)
Structure

151

MM-GBSA ∆GBind

Docking
score

-101.668

-7.933

Chapter 3
Probing the Binding Pathway of BRACO19 to a Parallel-Stranded Human
Telomeric G-Quadruplex Using Molecular Dynamics Binding Simulation with
AMBER DNA OL15 and Ligand GAFF2 Force Fields
3.1 Abstract
Human telomeric DNA G-quadruplex has been identified as a good therapeutic
target in cancer treatment. G-quadruplex specific ligands that stabilize the G-quadruplex,
have great potential to be developed as anticancer agents. Two crystal structures (an apo
form of parallel stranded human telomeric G-quadruplex and its holo form in complex with
BRACO19, a potent G-quadruple ligand) have been solved, yet the binding mechanism
and pathway remains to be elusive. In this study, we simulated the binding of a free
BRACO19 molecule to the apo form of the G-quadruplex using the latest AMBER DNA
(OL15) and ligand GAFF2 force field. Three binding modes have been identified: top
stacking, bottom intercalation and groove binding. Bottom intercalation (51% of the
population) resembles the bottom binding pose in the complex crystal structure very well.
The groove binding mode is less stable than the bottom binding mode, and is likely to be
an intermediate state leading to bottom binding mode. A flip-insertion mechanism was
observed in the bottom intercalation mode, during which the flipping out of the bases made
space for ligand insertion, followed by bases flipping back to increase the stability of the
complex. In addition to reproducing correct base-flipping behavior for some loop residues
upon the ligand binding, the direct alignment type of ATAT-tetrad was observed in our
simulations for the first time. These successes provide an initial support for using this force
field combination of OL15 and GAFF2 force fields to study quadruplex/ligand interactions.
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3.2 Introduction
In a guanidine-rich sequence, the formation of eight Hoogsteen H-bonds between
four guanine bases instead of the typical Watson–Crick H-bonds observed in duplex DNA,
leads to a square-planar configuration known as G-tetrad. And multiple G-tetrads further
stack together to form a G-quadruplex. G-quadruplex can be formed by one, two or more
strands of DNA or RNA and can fold into diverse topologies.(Burge, Parkinson, Hazel,
Todd, & Neidle, 2006) The electron dense void generated by the oxygens of the adjacent
guanidine bases are typically filled by a monovalent cation stabilizing the whole Gquadruplex structure. And as the K+ and Na+ are the pronounced cations, the Gquadruplexes with these cations are physiologically favored. Accounting to the better coordination of K+ with eight oxygens of four guanidine bases, it is preferred over Na+.(Burge
et al., 2006; Collie, Sparapani, Parkinson, & Neidle, 2011) Computational tools have
identified over 350,000 putative G-quadruplex sequences in the human genome, both the
promoter regions of genes as well as within telomeres. (Huppert & Balasubramanian, 2005,
2007) Evidence supporting G-quadruplex formation in human cells has been reported in
various studies.(Biffi, Tannahill, McCafferty, & Balasubramanian, 2013; Di Antonio,
Rodriguez, & Balasubramanian, 2012; Hänsel et al., 2009; Hänsel et al., 2011b; Hänsel,
Löhr, Trantirek, & Dötsch, 2013) In particularly, G-quadruplexes are over-represented
specifically in areas of DNA damage in cancer cells and happen to appear more frequently
in tumors than in normal tissues.(Cree & Kennedy, 2014; Duchler, 2012; Onel, Lin, &
Yang, 2014; Shalaby et al., 2013) For that reason, G-quadruplexes are becoming important
pharmacological targets for developing cancer therapeutics.(Balasubramanian, Hurley, &
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Neidle, 2011; Cree & Kennedy, 2014; Duchler, 2012; Onel et al., 2014; Shalaby et al.,
2013)
The first therapeutically important G-quadruplex formation was observed in the 3’end overhang of human telomeric DNA(Doluca, Withers, & Filichev, 2013b). The
telomeric overhang with a length of 100-200 nucleotides, containing repeats of the
sequence d(TTAGGG), is capped by Shelterin complexes.(Chung et al., 2013b; de Lange,
2005b; Moyzis et al., 1988b; Wright, Tesmer, Huffman, Levene, & Shay, 1997a) After
each cell replication, the telomere truncates by 50-200 base pairs and when the telomere is
exhausted and Hayflick limit is reached, cell senescence and apoptosis are
triggered(Harley, Futcher, & Greider, 1990b; Zakian, 1995b). In cancer cells, a reverse
transcriptase called telomerase which is overexpressed in 80-85% of tumor cells, adds
nucleotides to the telomere thus immortalizing the cells.(Greider & Blackburn, 1989a;
Moorhouse et al., 2006b) It has been reported that the telomere cannot be hybridized by
telomerase when the 3’ overhang folds into a G-quadruplex (Zahler, Williamson, Cech, &
Prescott, 1991b), leading to the inhibition of telomerase and thus cell apoptosis. In addition,
the telomeric G-quadruplex adopted by the guanidine-rich 3’ overhang prevents the
binding of telomere protection proteins, which causes chromosomal fusions and stimulate
cell apoptosis.(Denchi & de Lange, 2007b; Doluca et al., 2013b) Therefore, the Gquadruplex ligands that stablize the G-quadruplex are considered as promising anti-cancer
agents and are under intensive development.(Hänsel et al., 2011b) Tricyclic aromatic
chromophore based G-quadruplex binding molecules has been identified. The activity of
these molecules was optimized by substituting side chains with amido-alkylamino
character. A study by Read et al. on telomeric inhibitors makes the best case for BRACO19
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reporting better proportion between IC50 of 10-13 µM against various ovarian tumor cell
lines and telomeric inhibition EC50 of 95 nM compared to other molecules of the same
class.

Figure 29. Chemical structure of BRACO19 (3+).

BRACO19 (Figure 29), a computationally designed G-quadruplex ligand targeting
the parallel-stranded G-quadruplex binding site(Yang & Okamoto, 2010b), inhibits
telomerase, causes telomere shortening and also produces end-to-end chromosomal fusions
in cancer cells. (Incles et al., 2004) It shows significant in-vivo anticancer activity in
various tumor cell lines (Table 110)(Akagi & Kimoto, 1976; Alizadehnohi, Nabiuni,
Nazari, Safaeinejad, & Irian, 2012; Brandes & Hermonat, 1983; Burger et al., 2005; Chen,
Drabkowski, Hay, Macy, & Peterson Jr, 1987; Fang & Aust, 1997; Gunaratnam et al.,
2007; Harrison et al., 2004; Kellner, Wierda, Shpall, Keating, & McNiece, 2016a; Landers,
Cassel, & George, 1997; Mickey et al., 1977; Morimoto, Safrit, & Bonavida, 1991b;
Nichols et al., 1977; Olopade et al., 1992b; Rankin, Faller, & Spanjaard, 2008a; G. T. Zhou
et al., 2016).
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Table 110
In vivo activity of BRACO19 against various cancer cell lines.
Cell lines
Tissue type
IC50
MCF7
Breast cancer (human)
2.5 μM
(Brandes & Hermonat, 1983)
(Gunaratnam et al., 2007)
A549
Lung cancer (human)
2.4 μM
(Fang & Aust, 1997)
DU145
Prostate cancer (human)
2.3 μM
(Mickey et al., 1977)
HT-29
Colon cancer (human)
2.7 μM
(Chen et al., 1987)
HGC-27
Gastric carcinoma
2.6 μM
(Akagi & Kimoto, 1976)
A2780
Ovarian cancer (human)
2.5 μM
(Alizadehnohi et al., 2012)
WI-38
Lung fibroblast (human)
10.7 μM
(Landers et al., 1997)
(Gunaratnam et al., 2007)
IMR90
Lung fibroblast (human)
>25 μM
(Nichols et al., 1977)
U87
Glioblastoma (human)
1.45 μM
(Olopade et al., 1992a)
(G. T. Zhou et al., 2016)
U251
Glioblastoma (human)
1.55 μM
SHG-44
Glioma (human)
2.5 μM
UXF1138L
Uterus carcinoma (human)
2.5μM
(Burger et al., 2005)
CH1
Lymphoma (mouse)
10.1μM
(Harrison et al., 2004)
SKOV3
Ovarian cancer (human)
13.0μM
(Morimoto, Safrit, & Bonavida, 1991a)
CLL
Chronic lymphocytic leukemia
80μM
(Kellner, Wierda, Shpall, Keating, &
(Rankin, Faller, &
McNiece, 2016b)
Spanjaard, 2008b)
AML
Acute myeloid leukemia
80μM
(Rankin et al., 2008a)
-Prolymphocytic leukemia
80μM
(Rankin et al., 2008a)

In addition, BRACO19 also demonstrates broad anti-viral activity by stabilizing the
G-quadruplexes found in pro-viral DNA.(Perrone et al., 2014) The crystal structure of a
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parallel telomeric G-quadruplex d(TAGGGTTAGGGT)2 with and without BRACO19
(PDB ID: 3CE5 and 1K8P, respectively) have been identified (Figure 30).

A

C

B

D

E

F
A8

A8

T6

T24

T7 T6

T24

Figure 30. Comparison between apo and holo crystal structure of a parallel telomeric DNA
G-quadruplex. (A) The holo structure of the telomeric DNA G-quadruplex in complex with
BRACO19 (PDB: 3CE5). (B) Superimposition of the apo and holo form. (C) Cartoon
representation of the holo form highlighting the four layers formed by DNA bases. (D) The
holo structure of the telomeric DNA G-quadruplex in complex with BRACO19 at the
bottom (PDB: 3CE5). (E) Cartoon representation of the apo form highlighting the five
layers formed by DNA bases. (F) The apo form of the telomeric DNA G-quadruplex (PDB:
1K8P).

In the holo form, BRACO19 molecule binds at the interface of two parallel folded
G-quadruplexes, sandwiched between a G-tetrad and a AT tetrad (Figure 31), where ATA
is from the bottom G-quadruplex and T is from the top G-quadruplex.
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Figure 31. Quadruplex-ligand-quadruplex interface in crystal structure.

The comparison of the holo form with the apo form indicates that the binding of
BRACO19 induces some local conformational changes in the G-quadruplex. First, the
bases of T6, T7 and A8 flip out in the holo form with respect to the apo form, probably
facilitating the insertion of the 3-pyrrolodino-propionamido branch of BRACO19. Second,
the two adenine bases (residues 2 and 14) and the two thymine bases (residues 1 and 13)
are paired in the apo form whereas in the holo form, the residues 1, 2 and 14 in are paired
leaving the thymine residue, 13, unpaired. These local conformational adjustments clearly
indicate that the intercalation of BRACO19 into the G-quadruplex follows an induced-fit
binding mechanism rather than lock-key. Yet, the binding pathway and detailed mechanism
remain elusive. The induced fit binding mechanism proposes that the initial weak binding
interactions between ligand and receptor induce conformation changes in the receptor and
ligand; and these changes in turn facilitate better binding affinity and specificity. Therefore
understanding the binding pathway of BRACO19 to telomeric DNA G-quadruplex is
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essential in designing more potent drugs. Furthermore, this intercalation mode with these
subtle local conformational changes from the experimental structure also provides an
excellent test to check whether molecular dynamics (MD) simulation based on the latest
force fields is accurate enough to reproduce this binding mode.
MD stability simulations with various force fields have been widely used in
studying G-quadruplexes in complex with BRACO19 and other ligands. Moore et al
modelled 22mer parallel G-quadruplex with BRACO19 analogs; and conducted MD
simulations to probe the qualitative structure-activity relationships (Moore et al., 2006a)
using the AMBER parm99 force field.(Cornell et al., 1996; Jorgensen, Chandrasekhar,
Madura, Impey, & Klein, 1983b; J. M. Wang, Cieplak, & Kollman, 2000; J. M. Wang, R.
M. Wolf, J. W. Caldwell, P. A. Kollman, & D. A. Case, 2004) Hou et al conducted stability
simulations using the AMBER parm99 force field(Duan et al., 2003; J. M. Wang et al.,
2004) on G-quadruplex in complex with BRACO19 and 5 other ligands; and revealed that
the H-bonds in the G-quadruplex to be major contributors for the stability of the Gquadruplex and ligand-quadruplex complex.(J. Q. Hou et al., 2010a) Dhamodharan et al
docked bis-quinolinium and bis-pyridinium derivatives of 1,8-naphthyridine to an
antiparallel G-quadruplex and consequently, conducted MD simulations; and reported that
end-stacking was the favored binding mode.(Dhamodharan, Harikrishna, Jagadeeswaran,
Halder, & Pradeepkumar, 2012b) Jain et al docked dimeric 1,3-phenylene-bis(piperazinyl
benzimidazole)s to a 22mer parallel G-quadruplex, ran MD simulations and reported that
both end-stacking and groove-binding were favored.(Jain, Paul, Maji, Muniyappa, &
Bhattacharya, 2012a) Using docking and MD simulations based on AMBER
parm99(Akhshi, Mosey, & Wu, 2012; Biffi, Tannahill, Miller, Howat, & Balasubramanian,
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2014; Di Leva, Novellino, Cavalli, Parrinello, & Limongelli, 2014) force field, Ungvarsky
et al successfully characterized the binding pose of a set of novel BRACO19 derivatives to
the human telomeric parallel G-quadruplex.(Ungvarsky et al., 2014a) Zhou et al employed
steered molecular dynamics and umbrella simulations using the charmm27 force
field(MacKerell et al., 1998) to understand the ligand unbinding from human telomeric
antiparallel G-quadruplex.(J. K. Zhou, Yang, & Sheu, 2015a) Recently, Diveshkumar et al
identified indolyl, methylene-indanone scaffolds, by docking and conducting MD
simulations using AMBER DNA parm99 force field with the updates of parmbsc0 and
χOL4 refinement(Cheatham, Cieplak, & Kollman, 1999; Krepl et al., 2012a) on various Gquadruplexes (PDB IDs: 2L7V, 2O3M, 1KF1, 143D, and 2MB3), which specifically binds
to parallel promoter G-quadruplexes rather than telomeric DNA G-quadruplex or duplex
DNA(Diveshkumar et al., 2016a). However, these stability simulations don’t provide
detailed information on the binding pathway.
A recent AMBER DNA force field OL15 has been developed to include the
corrections on several backbone torsional angle parameters (i.e. βOL1(Zgarbová et al.,
2015), εζOL1(Zgarbová et al., 2013)and χOL4(Krepl et al., 2012a) to ff99bsc0(GalindoMurillo et al., 2016)). These corrections are expected to improve the backbone sub-state
description in G-quadruplexes and Z-DNA. So far, the tests on a DNA force field is mainly
limited to long stability simulations on various DNA systems including B-DNA, Z-DNA,
duplexes, triplexes, G-quadruplexes as well as unfolding simulations of DNA
duplex.(Galindo-Murillo et al., 2016; Ivani et al., 2016; Sponer, Cang, & Cheatham, 2012;
Zgarbová et al., 2013; Zgarbová et al., 2015) The performance of this DNA force field
coupled with a recently updated AMBER GAFF2(J. M. Wang et al., 2004) ligand force
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field on the binding simulations of ligand to G-quadruplexes is yet to be validated. During
which the local unfolding and refolding of the bases particularly, base flipping is expected
and thus provide a good test for the backbone torsional angle parameters of the improved
DNA force field OL15. In this study, MD free binding simulations of unbound ligandDNA complex were utilized to probe the binding pathway and mechanism of BRACO19
to the human telomeric parallel G-quadruplex DNA and stability simulations of two crystal
binding poses were used to generate reference structures under physiological solution
conditions and to understand the limitations of X-ray crystal packing. While the crystal
bottom pose was stable, the crystal top pose altered significantly. In our free binding
simulations, the three major binding modes were observed: top stacking, bottom
intercalation and groove binding modes. The most abundant mode, the bottom intercalation
mode, resembles the MD relaxed crystal pose well. Encouragingly, the local conformation
adjustments were observed in the simulated structures. For the bottom intercalation mode,
these conformational changes are consistent with the crystal pose in terms of the backbone
torsion angles. These provide an initial evidence to the correctness of the torsion parameter
corrections made to the OL15 force field. The dynamic and energetic properties of the three
major binding modes were thoroughly studied, providing vivid examples of induced-fit
binding mechanism.
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3.3 Methods

Table 111
Molecular dynamics simulations.
No. of
No. of
K+ Box Size
Drug Initial NPT
DNA
Water
Runs
Ligands
ions (Å)1*
Pose
eq. (ns)
molecules
N/A
1
1491
3 Cl41.5
1
N/A
1
2
G-Quad(1K8P)
0
5141/4639 20/22 62.5/60.9 2x1
N/A
1
G-Quad(3CE5)
1
5114
17
62.5
1
top pose
1
G-Quad(3CE5)
1
5075
19
62.5
1 bottom pose
1
G-Quad(1K8P)
1
7621
19
70.0
10
Free
1

NVT
(ns)
499
499
999
999
499

3.3.1 Simulation systems.

A
B
C
Figure 32. The initial configuration of the simulation system (DNA Quadruplex +
Unbound BRACO19). 5’ and 3’ of the telomeric G-quadruplex DNA are indicated by a red
and blue ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12,
24 are indicated in red and the K+ ions are represented in yellow.

1
2

Triclinic box equivalent to the true truncated octahedral box
2 DNA structures: 1K8P top /1K8P bottom G-quadruplex with 2 missing residues (cf. Simulation system)
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A DNA-ligand system was constructed, using the X-ray solved human telomeric
DNA G-quadruplex (Figure 32C, PDB ID: 1K8P(Parkinson, Lee, & Neidle, 2002)) with
an unbound BRACO19 10 Å away from the G-quadruplex, to simulate 10 simulation runs.
This 10 Å distance was to ensure that there were at least three layers of water molecules
separating ligand and DNA, and thus enabling the simulations to start from an unbound
state to probe the binding pathways and mechanisms. The four non-standard brominated
Uracil residues were replaced by standard Thymine residues in the original PDB structure.
Two bound DNA-ligand systems, one characterizing bottom intercalation mode (Figure
32A, BRACO19 stacked below the G-tetrad formed by residues G5, G11, G17 and G23)
and other characterizing top stacking mode (Figure 32B, BRACO19 stacked above the
ATA formed by residues A2, T13 and A14) were constructed from the bound X-ray solved
human telomeric DNA G-quadruplex (PDB ID: 3CE5) and simulated. Note that the crystal
structure characterizing top stacking mode is missing two terminal residues, G23 and T24,
in the second chain. A water box of a truncated octahedron, 10 Å water buffer and K+ to
act as counter ions, was used to solvate the unbound and bound systems. For the unbound
system, the water buffer starts from the outmost atom of the ligand to the box surface. A
TIP3P model (Jorgensen, Chandrasekhar, Madura, Impey, & Klein, 1983a) represented the
water molecules, a K+ model recently developed by Cheatham group and a refined version
of the AMBER OL15 with the addition of corrections βOL1, εζOL1 and χOL4 to ff99bsc0
(Galindo-Murillo et al., 2016) represented the DNA G-quadruplex(Joung & Cheatham,
2008a). The standard AMBER protocol was used to generate the partial charges of
BRACO19 with 3+ charge at physiological pH=7; HF/6-31G* level was used to obtain the
electrostatic potential after the geometrical optimization and the RESP (Restrained Electro-
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Static Potential) method was then used to generate the partial charges(Bayly, Cieplak,
Cornell, & Kollman, 1993b) and AMBER GAFF2(J. M. Wang et al., 2004) force field
provided the other parameters.
3.3.2 Simulation protocols. The AMBER 16 package(Case et al., 2016) was used
to conduct 12 simulation runs for the unbound DNA-ligand system, 1 simulation run for
BRACO19 only and 1 simulation for G-Quadruplex only (Table 111). After the potential
energy of the system was minimized, 14 independent simulation runs were conducted with
different initial velocities, which were assigned based on random seeds. For the free
binding system, an extra 500 ps pre-run at high temperature (500 K) was carried out to
randomize the position and orientation of the free ligand(Lei, Wang, & Wu, 2012a), while
the receptor was fixed. A short 1.0 ns molecular dynamics in the NPT ensemble mode
(constant pressure and temperature) was used to relax the system density with cartesian
restraints (1.0 kcal/mol/Å) on the ligand and the G-quadruplex and then 499.0 ns dynamics
for unbound systems and 999.0 ns dynamics for bound systems in the equivalent NVT
ensemble mode (constant volume and temperature) was run at 300 K. 2.0 fs time step was
enabled in the simulations by applying SHAKE(Ryckaert, Ciccotti, & Berendsen, 1977a)
to constrain all bonds connecting hydrogen atoms. The long-range electrostatic interactions
were treated with the particle-mesh Ewald method(Essmann et al., 1995a) under periodic
boundary conditions (charge grid spacing of ~1.0 Å, the fourth order of the B-spline charge
interpolation; and direct sum tolerance of 10–5 ). For the short-range non-bonded
interactions, the cutoff distance was 10 Å; and the long-range van der Waals interactions
were based on a uniform density approximation. A two-stage RESPA approach(Procacci
& Berne, 1994a) was used in calculating the non-bonded forces, where the frequency of
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updating short range forces was once per time step and long range forces was twice per
time step . The Langevin thermostat with a coupling constant of 2.0 ps was used to control
the temperature. The trajectories were saved at 100.0 ps intervals for analysis.
3.3.3 Convergence of simulations. The root mean square deviation (RMSD) of
DNA backbone and ligand-DNA atom contacts using a cutoff of 3.0 Å were used to
monitor the convergence of the simulations. Attaining a steady bound state and the stability
of the bound state was indicated by the flat and small RMSD of 2.5 Å (Figure 60) and the
stable contact number (Figure 61) in the last 200 ns. A complex with the number of atom
contacts greater than 40 is defined as a stable complex. A good sampling of the binding
sites is indicated by the free drugs are binding to different sites as shown in the last
snapshots for the ten runs (Figure 33).

Front View

Top View

Front View

Top View

Run 01

Run 06

Run 02 (Top)

Run 07 (Bottom intercalation)

Figure 33. Last snapshots of the ten quadruplex-BRACO19 simulations. 5’ and 3’ of the
telomeric G-quadruplex DNA are indicated by a red and blue ball, respectively. Residues
1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red and the K+ ions
are represented in yellow.
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Front View

Top View

Front View

Top View

Run 03

Run 08

Run 04

Run 09 (Bottom intercalation)

Run 05

Run 10 (Groove)

Figure 33 (continued)

3.3.4 Binding mode identification. DNA backbone of the stable complexes from
the trajectories were aligned by least square fitting as the DNA backbone remained
relatively stable. Daura algorithm(Daura et al., 1999a) was used to cluster the aligned
complexes into different structural families based on the ligand’s 2 Å pair-wise RMSD
cutoff without fit. Every structural family is represented by the centroid structure. The
centroid structure of the populated structural families (>1% of total structure population)
are shown in Table 112. Based on visual inspection, these centroid structures were further
merged into three major binding modes: top stacking, bottom stacking and groove binding
modes.
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Table 112
Representative structures of the most populated complex structure families (population ≥
1 %) from the clustering analysis of the combined binding trajectories. 5’ and 3’ of the
telomeric G-quadruplex DNA are indicated by a red and blue ball, respectively. Residues
1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red.
Binding model

Top Stacking

Cluster ID

A1

Representative Structure
(Front View)

Representative Structure
(Top View)

Representative Structure
(Side View)

Population

11.9%
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Table 112 (continued)
Binding model
Cluster ID

End Intercalation (Bottom)
B1

B2

B3

44%

5.3%

1.8%

Representative
Structure
(Front View)

Representative
Structure
(Bottom View)

Representative
Structure
(Side View)

Population
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Table 112 (continued)
Binding model
Cluster ID

Groove Binding
C1

C2

8.3%

1.3%

Representative
Structure
(Front View)

Representative
Structure
(Lateral View)

Representative
Structure
(Side View)

Population

3.3.5 Parameters for characterizing DNA-drug binding pathway. The DNAdrug binding process was characterized by five order parameters: MM-PBSA binding
energy (ΔE), center-to-center distance (Å), K+-K+ distance, ligand RMSD, drug-base
dihedral angle, and hydrogen bond analysis. In order to avoid large energy fluctuation of
explicit solvent, the energetics of the bound complexes were analyzed using MMPBSA(Tan, Tan, & Luo, 2007) (Molecular Mechanics Poisson-Boltzmann/Surface Area)
module in the AMBER package (PB1 model with mBondi radii set, salt concentration of
0.2 M, and surface tension of 0.0378 kcal/mol/Å2 and offset of -0.5692 kcal/mol). And
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MM-GBSA(Gregory D. Hawkins, Christopher J. Cramer, & Donald G. Truhlar, 1995;
Hawkins, Cramer, & Truhlar, 1996; Tsui & Case, 2000) (Molecular Mechanics
Generalized-Born/Surface Area) module in AMBER package (GB1 model with mBondi
radii set, at various ionic strengths of 0.0 M, 0.05 M, 0.1 M, 0.15 M and 0.2 M, and surface
tension of 0.00720 kcal/mol/Å2) was also used to characterize the binding affinities of
different binding modes. An evaluation study by Case et al. suggested that the GB1 model
performs better than GB2-OBC1 and GB5-OBC2.(Gaillard & Case, 2011) To include the
conformation energy change, the MM-PBSA/MM-GBSA binding energy for a system was
calculated from three simulations(Kelly Mulholland, Siddiquei, & Wu, 2017): ligand only,
DNA only and DNA-ligand complex. The center-center distance was defined as the
distance between the center of the DNA G-quadruplex and BRACO19. The K+-K+ distance
is defined as the distance between the K+ ions in the G-quadruplex DNA. Receptor and
ligand RMSD for bottom and groove binding mode were calculated with reference to the
last snapshot of the simulation of bound crystal complex characterizing bottom
intercalation mode (PDB ID: 3CE5); and receptor and ligand RMSD for top stacking was
with reference to the last snapshot of the simulation of bound crystal complex (PDB ID:
3CE5) characterizing top stacking mode. The dihedral angle was defined as the angle
between the plane of the top layer of the G-tetrads of the DNA G-quadruplex and the
BRACO19’s center, the plane of the acridine ring. The geometric definition of H-bonds:
distance cutoff between the donor and acceptor was 3.5 Å and the angle cutoff between the
same with -H was 120°. The H-bonds were defined and calculated for the five base layers
over the course of the trajectories: the first/AT-tetrad (T1, A2, T13 and A14), the
second/top layer of the G-tetrads (G3, G9, G15 and G16), the third/middle layer of the G-
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tetrads (G4, G10, G16 and G22) the fourth/bottom layer of the G-tetrads and the fifth/Tdyad (T12 and T24) illustrated in (Figure 71). The standard backbone dihedral angles (α,
β, γ, δ, ε and ζ) around the covalent bonds of the deoxyribose and χ about the glycosidic
bond were defined to characterize the conformational changes. The defined dihedral angles
are depicted in Figure 34.

Figure 34. Backbone Torsion Angles of DNA.

3.4 Results
Two bound DNA-ligand systems, one characterizing bottom intercalation mode
and other characterizing top stacking mode, were simulated to characterize the stability of
the binding modes observed in the X-ray solved human telomeric DNA G-quadruplex
(Figure 30, PDB ID: 3CE5).
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Figure 35. Stability simulation of the bottom binding mode in the crystal structure (PDB:
3CE5). Top: Representative structures with time annotation. 5’ and 3’ are indicated by a
red and blue ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues
12, 24 are indicated in red and the K+ ions are represented in yellow. Bottom: An order
parameter plot depicting number of hydrogen bonds present in first (red), second G4
(cyan), third G4 (blue), fourth G4 (black) and fifth (green) layers of the DNA structure
(Figure 71), the drug-base dihedral angle, receptor (red) and ligand (black) RMSD relative
to the original crystal pose, center-to-center distance (R/black) and K+-K+ distance (R/red)
and MM-PBSA binding energy (ΔE) (cf. methods section for definition).
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3.4.1 The crystal bottom intercalation mode of BRACO19 was stable. The
simulation of DNA-ligand system characterizing bottom intercalation mode illustrated a
stable binding mode (Figure 35) as indicated by the small receptor and ligand RMSD and
drug-base dihedral angle in the order parameter plot. The planarity observed in the crystal
structure (Figure 37A) is lost and conformational changes are observed in 3-pyrrolodinopropionamido branches of BRACO19. This loss of planarity is explained by the absence
of stacking between two tetrads, G-tetrad and an ATAT-tetrad, as observed in the crystal
structure (Figure 31). The ligand interactions of BRACO19 with the G-quadruplex in
crystal structure (bottom pose) and MD relaxed crystal structure (bottom pose) are
compared (Figure 70).
And the final MD relaxed crystal structure illustrated (i) the acridine ring stacked
on residue, G5 (ii) the protonated N in the acridine ring formed a H-bond with T12, (iii)
the 3-pyrrolodino-propionamido side chain at the 6th position formed a H-bond with G17
and (iv) the other 3-pyrrolodino-propionamido side chain at the 3rd position formed a Hbond with G11 (Figure 70 (B)) whereas in the crystal structure the acridine is stacked on
residues G5 and G23 and the N from the amide of the 3-pyrrolodino-propionamido side
chain on 3rd position formed a H-bond with T12 (Figure 70 (A)). Formation of TT-dyad
and ATAT-tetrad are also observed (Figure 71) and illustrated in the order parameter plot
by increase in the number of H-bonds (Figure 35). This explains that its formation was
blocked in the crystal structure due to crystal packing constraints.
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Figure 36. Stability simulation of the top binding mode in the crystal structure (PDB:
3CE5). Top: Representative structures with time annotation. 5’ and 3’ are indicated by a
red and blue ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues
12, 24 are indicated in red and the K+ ions are represented in yellow. Bottom: An order
parameter plot depicting number of hydrogen bonds present in first (red), second G4
(cyan), third G4 (blue), fourth G4 (black) and fifth (green) layers of the DNA structure
(Figure 71), the drug-base dihedral angle, receptor (red) and ligand (black) RMSD relative
to the original crystal pose, center-to-center distance (R/black) and K+-K+ distance (R/red)
and MM-PBSA binding energy (ΔE) (cf. methods section for definition).
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3.4.2 The crystal top mode of BRACO19 changed significantly, caused by lack
of crystal packing constraints. The simulation of DNA-ligand system characterizing top
stacking mode illustrated an unstable binding mode. The ligand moves away from the Gquadruplex and binds again although not in the same orientation as illustrated in Figure 36.
This is demonstrated by the ligand RMSD and drug-base dihedral angle. Concluding that
the top stacking mode is due to crystal packing constraints. The ligand interactions of
BRACO19 with the G-quadruplex in crystal structure (top pose) and MD simulated crystal
structure (top pose) are compared (Figure 70). And the final MD simulated crystal structure
illustrated (i) acridine ring stacked on residue A14, in the 3-pyrrolodino-propionamido side
chain at the 6th position, (ii) the pyrrolodino ring formed a H-bond with A2 and (iii) the O
from the amide formed H-bond with A14 and in other 3-pyrrolodino-propionamido side
chain at the 3rd position, (iv) the pyrrolodino ring formed a H-bond with A14 and (v) the
protonated N in the acridine ring was also interacting with A14 (Figure 70 (E)) whereas in
the crystal structure the acridine is stacked on A14 and the side chain at the 6 th position
formed a salt bridge with G21 (Figure 70 (D)). The K+ ion moves out of the G-quadruplex
(Figure 36), this might be caused by the two missing terminal residues.
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Bottom Intercalation MD Relaxed Crystal MD Relaxed Crystal
(51.1%)
Pose (Top)
Pose (Bottom)

Front View

Lateral View

A8
T7

T6
A8
T7

T6
A8

T13

T7 T6

Top Stacking
(11.9%)

A8
T7

Groove Binding
(9.6%)

T6
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T7
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Figure 37. The MD relaxed crystal structure of (A) bottom intercalation mode and (B) top
stacking mode (PDB ID: 3CE5) and the major binding modes, (C) bottom intercalation
mode (D) top binding mode and (E) groove binding mode from the binding simulations.
BRACO19 is shown in licorice; 5’ and 3’ of the telomeric G-quadruplex DNA are indicated
by a red and blue ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and
residues 12, 24 are indicated in red for lateral view and the K+ ions are represented in
yellow.
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3.4.3 Three drug binding modes were observed in free binding DNA-ligand
simulations. 10 simulation runs (500 ns of each) were executed to study the binding
pathway of BRACO19 to the telomeric DNA G-quadruplex. The convergence of the
binding simulations was confirmed (see the method section). Starting at an unbounded
state, the ligand was observed to bind to the top and bottom of the G-quadruplex in seven
runs (run 2, 3, 4, 5, 6, 7 and 9, Figure 33) and to the groove/side of the G-quadruplex in the
remaining three runs (run 1, 8 and 10, Figure 33) at 500 ns. Six structural families with
over 1% population were obtained from the clustering analysis (Table 112). Three binding
modes were identified from these six structural families (Figure 37): top stacking (11.9 %
of the total population), bottom intercalation (51.1%) and groove binding (9.6%).
Encouragingly, the bottom pose is very similar to the ligand pose in the crystal complex
structure (Figure 37A, 37C). In the bottom-intercalation mode, BRACO19 is sandwiched
between the bottom G-tetrad and T-dyad. This pose is very consistent with the bottom
intercalation pose of BRACO19 in the crystal structure (Figure 37A, 37C): a) the similar
position and orientation of BRACO19; b), the intercalation between G-tetrad and T-dyad;
c) flipping out of the bases A8 and T7. Subtle differences were also observed: a). a higher
planarity of BRACO19 in the crystal structure; b) flipping out of T6 in the crystal structure;
c). pairing between T12 and T24 in the MD structure.
The high planarity of BRACO19 in the crystal structure might be accounted by the
fact that it is stacked between an ATAT-tetrad and a G-tetrad; and the paring between T12
and T24 is blocked by the formation ATAT-tetrad in the crystal structure (Figure 31). This
ATAT-tetrad comprises a thymine residue from the top G-quadruplex and two adenine
bases and one thymine base from the bottom G-quadruplex. Nonetheless, the ligand RMSD
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between the MD simulated structure and the crystal structure for this pose is ~1 Å,
indicating the high accuracy of the MD prediction. In the top binding pose, BRACO19
stacks on the top of the ATAT-tetrad, which is formed on the top of the first G-tetrad
(Figure 37D). In addition, the pairing between T12 and T24 and the flipping in of the bases
T6, T7 and A8 are observed in the top binding pose. In the groove binding mode,
interaction of BRACO19 with the groove, pairing between T12 and T24 and flipping out
of the bases T6, T7 and A8 are observed (Figure 37E). The groove binding pose appears
to be the intermediate binding pose of the end binding mode based on our binding pathway
(will be further discussed later). To characterize the conformational changes in the DNA
backbone upon binding, the dihedral angles were calculated for each residue in every
binding mode and compared with the simulated crystal poses. For the stability simulations
of the X-ray poses and the free binding simulations, the residues in three G-tetrads show
minimum fluctuations whereas the residues in terminal layers, ATAT-tetrad and T-dyad
larger fluctuations were observed. Encouragingly, the dihedral angles of the residues in the
representative structures of free binding simulations are consistent with most of the
residues in the crystal structures of stability simulations. This data supports the torsional
parameter corrections (βOL1, εζOL1 and χOL4) to the OL15 DNA force field.
3.4.4 The stable G-Quadruplex backbone scaffold is maintained as indicated
by the flat and small RMSD of ~2.5 Å in all trajectories (Figure 60). For the five base
layers in the G-quadruplex (Figure 71), while the middle three G4 are the stable ones
(maintained in all the representative structures), the first and fifth layers are less stable and
modulated by ligand binding. Among the three G-tetrad layers, the most stable G-tetrad is
found to be the middle G-tetrad with ~10 H-bonds, followed by the top G-tetrad with ~8
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H-bonds and the bottom G-tetrad with ~5 H-bonds in all trajectories. The detailed account
of H-bonds maintained in the representative structure of different binding poses with
respect to the experimentally solved X-ray crystal structure is illustrated in Figure 71.
The binding pathway of the three binding modes was characterized by calculating
the five order parameters as described in the methods section. A representative trajectory
for each mode is shown in Figure 38, 40 and 42.
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248 ns
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Figure 38. A representative trajectory of the bottom intercalation mode. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue
ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are
indicated in red and the K+ ions are represented in yellow. Bottom: An order parameter
plot depicting number of hydrogen bonds present in first (red), second G4 (cyan), third G4
(blue), fourth G4 (black) and fifth (green) layers of the DNA structure (Figure 71), the
drug-base dihedral angle, receptor (red) and ligand (black) RMSD relative to the crystal
pose, center-to-center distance (R/black) and K+-K+ distance (R/red) and MM-PBSA
binding energy (ΔE) (cf. methods section for definition).
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3.4.5 Bottom intercalation of BRACO19 follows the flip-insertion mechanism.
In the representative trajectory of the bottom intercalation mode (Figure 38), the first
interaction between the G-quadruplex and BRACO19 occurred at about 2 ns from the
starting unbound state. Interestingly, successful intercalation of BRACO19 was observed
at 248 ns as the bases of T12 and T24 paired over BRACO19 and the bases, A8 and T7
flipped out. It was noted that the initial contact with the G-quadruplex is concurrent with
flipping out of the residues, T12 and T24 making space for BRACO19 to interact with Gtetrad. Once BRACO19 stacked below the bottom G-tetrad, the bases of T12 and T24
flipped back and paired to form two hydrogen bonds (Figure 71). As a result, the ligand is
sandwiched between the bottom G-tetrad and the T-dyad of the G-quadruplex, leading to
a stable intercalation mode with stable order parameters (ligand RMSD of ~1 Å and MMPBSA binding energy of ~-30 kcal/mol). Clearly, the drug binding facilitates the formation
of T-dyad (Figure 38). We name this intercalation as “flip-insertion” mechanism. This
mechanism is also observed in the other representative trajectory of bottom intercalation
mode. The ligand interactions of BRACO19 with the G-quadruplex in MD relaxed crystal
structure (bottom pose) and the representative structure of bottom intercalating trajectory
from the free binding simulation are compared (Figure 70). And the final MD simulated
crystal structure illustrated (i) the acridine ring stacked on residue G5, (ii) the protonated
N in the acridine ring formed a H-bond with T12, (iii) the 3-pyrrolodino-propionamido
side chain at the 6th position formed a H-bond with G17 and (iv) the other 3-pyrrolodinopropionamido side chain at the 3rd position formed a H-bond with G11 (Figure 70 (B))
whereas in the representative structure of bottom intercalating trajectory from the free
binding simulation (i) the acridine is stacked on G23, (ii) one pyrrolidine ring formed H-
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Figure 39. Comparison for the backbone torsion angles of residue T7 between the free ligand binding simulation
(red) and the stability simulation of the crystal pose (black) for the bottom intercalation mode.

bond with T18, (iii) other formed H-bond with T12 and G11 and (iv) the side chain on 9th

position is stacked on G5 (Figure 70 (C)).
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Another notable feature in this trajectory is the flipping out of the bases A8 and T7
after the intercalation of BRACO19. This flipping out of the bases is also observed in the
experimental X-ray solved crystal structure of G-quadruplex in complex with BRACO19,
PDB ID: 3CE5 (Figure 30). These conformational changes are characterized by calculating
the backbone dihedral angles of each base and comparing with its corresponding base in
the stability simulation of the crystal bottom mode. Figure 39 features the dihedral angles
of residue T7 in both representative trajectories of free binding and stability simulations
characterizing the bottom intercalation mode. Starting at the different values, the torsional
angles ε and ζ of residues from MD simulated crystal structure and free binding simulations
converged. The changes in the torsional angles are concurrent with the flipping out of
residue T7 from 323 ns through the rest of the trajectory with fluctuations. Therefore,
correct torsional parameters appear to be critical for reproducing base flipping shown in
the crystal structures.
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Figure 40. A representative trajectory of the top stacking mode. Top: Representative
structures with time annotation. 5’ and 3’ are indicated by a red and blue ball, respectively.
Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red and
the K+ ions are represented in yellow. Bottom: A representative trajectory of the top
stacking mode. An order parameter plot depicting number of hydrogen bonds present in
first (red), second G4 (cyan), third G4 (blue), fourth G4 (black) and fifth (green) layers of
the DNA structure (Figure 71), the drug-base dihedral angle, receptor (red) and ligand
(black) RMSD relative to the crystal pose, center-to-center distance (R/black) and K+-K+
distance (R/red) and MM-PBSA binding energy (ΔE) (cf. methods section for definition).
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3.4.6 Top stacking of BRACO19 leads to the formation of ATAT-tetrad in a
trajectory. The representative trajectory for the top stacking mode is shown in Figure 40
with the 500-ns order parameter plot. In this trajectory, the first interaction of BRACO19
with the top of the G-quadruplex occurred at about 18 ns from the starting unbound state.
From about 18-42 ns of the trajectory, BRACO19 flipped orientation and the residues T1,
A2, T13, A14 formed an ATAT-tetrad and remained stable through the rest of the
simulation (ligand RMSD of ~3.5 Å and MM-PBSA binding energy of ~-25 kcal/mol).
The formation of ATAT-tetrad(Zhang et al., 2001) by residues T1, A2, T13, A14 in the
first layer is indicated by the fact that the number of H-bonds increases to ~6 from initial
~3 in the first layer at 42 ns.
The ligand interactions of BRACO19 with the G-quadruplex in MD simulated
crystal structure (top pose) and the representative structure of top stacking trajectory of free
binding simulation are compared (Figure 70). And the final MD simulated crystal structure
illustrated (i) acridine ring stacked on residue A14, in the 3-pyrrolodino-propionamido side
chain at the 6th position, (ii) the pyrrolodino ring formed a H-bond with A2 and (iii) the O
from the amide formed H-bond with A14 and in other 3-pyrrolodino-propionamido side
chain at the 3rd position, (iv) the pyrrolodino ring formed a H-bond with A14 and (v) the
protonated N in the acridine ring was also interacting with A14 (Figure 70 (E)) whereas in
the representative structure of top stacking trajectory of free binding simulation the N in
the acridine formed a H-bond with T13 and (ii) N from the amide of side chain on 6th
position formed a H-bond with A14 (Figure 70 (G)).
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Figure 41. Comparison for the backbone torsion angles of residue T7 between the free ligand binding simulation (red) and the
stability simulation of the crystal pose (black) for the top stacking mode.

Occasional flipping out of the bases in the loops is also observed in this trajectory.
Figure 41 features the dihedral angles of residue T7 in both stability simulation of the
crystal top mode and the representative trajectory of the free binding simulations
charactering top stacking mode. In the stability simulation trajectory, the residue T7 is
flipped out from 74 ns to 95 ns, from 110 to 129 ns and from 258 to 333 ns with fluctuations
mainly characterized by α and γ. In the free binding simulation trajectory, the residue T7
is flipped out from 322 ns to 345 ns and from 395 ns to 462 ns and is mainly characterized
by α, ε and ζ angles.
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Figure 42. A representative trajectory of the groove binding mode. Top: Representative
structures with time annotation. 5’ and 3’ are indicated by a red and blue ball, respectively.
Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red and
the K+ ions are represented in yellow. Bottom: An order parameter plot depicting number
of hydrogen bonds present in first (red), second G4 (cyan), third G4 (blue), fourth G4
(black) and fifth (green) layers of the DNA structure (Figure 71), the drug-base dihedral
angle, receptor (red) and ligand (black) RMSD relative to the crystal pose, center-to-center
distance (R/black) and K+-K+ distance (R/red) and MM-PBSA binding energy (ΔE) (cf.
methods section for definition).
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3.4.7 Groove binding of BRACO19 might be an intermediate state for the end
binding pose. In the representative trajectory of the groove binding mode, BRACO19
made initial contact with the telomeric G-quadruplex at 34 ns (Figure 42). At 20 ns, two
additional hydrogen bonds formed in the first base layer, indicating the formation of
ATAT-tetrad. At ~271 ns, the ligand moved to the groove, but rather than remaining stable,
it kept adjusting pose toward the G-quadruplex bottom end. This also was reflected in the
large fluctuation of the five order parameters during 200-450 ns. This system reached a
steady state at 450 ns, showing minor fluctuations through the rest of the trajectory. The
terminal MM-PBSA binding energy is ~20 kcal/mol, which is much lower than that of the
top stacking (-25 kcal/mol) and the bottom binding mode (~30 kcal/mol). Therefore, this
system can further be converted into an end binding pose. In fact, the conversion from a
groove binding pose to a bottom binding pose was observed at 236 ns in this trajectory
indicated by ligand RMSD and drug-base dihedral angle in the order parameter plot and
the conversion to a top binding pose was observed in another representative groove binding
trajectory. BRACO19 initially bound to the side of the telomeric G-quadruplex at 9 ns,
slightly moved down and bound to a groove at 86 ns, but moved out and bound to the top
at 345 ns, and then remained in this binding mode through the rest of the trajectory. The
van der Waals energy difference between groove binding pose and end binding pose might
be the driving force. The ligand interactions of BRACO19 with the G-quadruplex in the
representative structure of the groove binding trajectory and the representative structure of
the bottom trajectory are compared (Figure 70).
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Figure 43. Comparison for the backbone torsion angles of residue T18 between the free ligand binding simulation (red) of the groove
binding mode and the stability simulation of the crystal pose (black) of the bottom binding mode.

In the representative structure of the bottom intercalating trajectory (i) the acridine
is stacked on G23, (ii) one pyrrolidine ring formed H-bond with T18, (iii) other formed Hbond with T12 and G11 and (iv) the side chain on 9th position is stacked on G5 (Figure 70
(C)) whereas in the representative structure of the groove binding trajectory the acridine is
stacked on G17, (ii) pyrrolidine ring of side chain on 3rd position formed a H-bond with
G17, (iii) N from the amide of side chain on 6th position formed a H-bond with G23 and
(iv) the secondary amine from the side chain on 9th position formed a H-bond with T12
(Figure 70 (G)).
Occasional flipping out of the bases in the loops is also observed in this trajectory.
Figure 43 features the dihedral angles of residue T18 in representative trajectories of
stability simulations charactering crystal bottom intercalation mode and free binding
simulations charactering groove binding mode. In the stability simulation, the residue T18
does not flip out at all and this is characterized by the minimum fluctuation of ε and ζ. In
the free binding trajectory, the residue T18 is flipped out at 276 ns remains as such through
the rest of the trajectory and is mainly characterized by α, ε and ζ angles.

Table 113
MM-PBSA energy of BRACO19 to the G-Quadruplex DNA in different binding modes.
3 VDW
4 SUR
5 PB-ELE
6 CONF
7 TOT
8
Binding Pose
Δ
Δ
Δ
Δ
Δ
ΔΔE
Top Stacking
-60.1±6.2 29.4±3.3 11.2±5.5 -5.6±6.7 -25.1±6.7 4.2
Groove Binding
-42.7±5.3 22.2±3.0 6.5±6.1 -14.9±4.8 -26.1±6.6 3.2
Bottom Intercalation -84.8±4.2 36.6±1.8 18.0±5.0 0.9±2.7 -29.3±5.7
0
3

VDW = Change of VDW energy in gas phase upon complex formation (Units: kcal/mol)
SUR = Change of energy due to surface area change upon complex formation (Units: kcal/mol)
5
PB-ELE = Change of PB reaction field energy + Elec. energy upon complex formation (Units: kcal/mol)
6
CONF = Change of energy due to conformational changes (Units: kcal/mol)
7
TOT = (ΔVDW +ΔSUR + ΔPB-ELE + ΔCONF) Change of potential energy upon complex formation
8
ΔE = Difference to the most favorable binding mode
4
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3.4.8 MM-PBSA binding energy data ranks the bottom intercalation mode as
the most stable mode among the three binding modes. The relative stability of the three
binding modes was examined by conducting MM-PBSA binding energy calculations on
each mode. The best binding energy toward the G-quadruplex (-29.3±5.7 kcal/mol) is
observed in the bottom intercalation, making this the most favorable binding pose. The 25.1±6.7 kcal/mol and -26.1±6.6 kcal/mol binding energies of top stacking and groove
binding respectively are quite comparable. To further understand the nature of binding, the
binding energy was fragmented into van der Waals (VDW) interaction, hydrophobic
interaction (SUR), and electrostatic interaction (PB-ELE) (Table 113). As demonstrated in
the Table 113, most of the binding interactions are contributed by van der Waals
interactions. As expected, the most favorable VDW energy was demonstrated by the
bottom stacking pose (-84.8±4.2 kcal/mol), which is 24.7 kcal/mol more favorable than
that of top stacking pose and 42.1 kcal/mol more favorable than that of the groove binding
pose. This high VDW interactions of the bottom intercalation mode can be accounted by
the interaction of BRACO19 with a G-tetrad and a T-dyad whereas, the top stacking mode
and groove binding modes are only interacting with an ATAT-tetrad and the residues in
the loop, respectively. MM-GBSA binding energies were also calculated for each binding
pose of free binding simulations at various ionic strengths. The binding energies decreased
as the ionic strength increased indicating a stronger screening effect. But, the relative
binding energies of three modes at different ionic strength are quite similar, supporting the
use of MM-GBSA in ranking poses (ΔΔE=0.0, 4.6 and 6.5 kcal/mol for bottom, top and
groove binding modes). Clearly, both MM-PBSA and MM-GBSA data indicates the most
stable pose is the bottom binding mode and the groove binding mode is less stable, which
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was observed to convert into the end binding mode. Thus, the groove binding is likely an
intermediate state of end binding mode.
3.5 Discussion
G-quadruplex DNA has been gaining increasing attention as a promising target for
cancer therapeutics(Biffi et al., 2014). The binding of BRACO19 to the G-quadruplex
depends on its ability to π-π stack onto the G-quadruplex which is facilitated by its
planarity. Molecular dynamics binding simulations and MM-PBSA binding energy
calculations were utilized in this study, to analyze the binding pathway of BRACO19 to a
telomeric DNA G-quadruplex. To tackle the fore-mentioned question, whether the latest
AMBER DNA force field (OL15) is accurate enough to probe the binding pose of
BRACO19 to G-quadruplex, the complex obtained from the simulation of the apo form
and a free BRACO19 was compared to the simulated structure of the experimental X-ray
crystal structure of the bound form (PDB ID: 3CE5). Comparing with an NMR solved
structure would have been an ideal practice, but due to the unavailability of such NMR
structure, X-ray solved crystal structure was used. Because of the crystal packing
constraints, the potential AT-tetrad that could be formed by the bases T1, A2, T13 and A14
was disrupted and instead the AT tetrad was formed by A2, T13, A14 and the T24 (Figure
31) of different chains, thus disrupting the pairing of T24 with T12 of its respective chain.
In the previous X-ray study,(Chung et al., 2013a) only two binding modes were observed,
in which BRACO19 intercalates at the bottom of the G-tetrad and stack on the top of the
ATAT-tetrad (Figure 30A). Stability simulations were conducted on these two crystal
binding poses and illustrated the loss of planarity of BRACO19 in the bottom mode and
instability of top stacking mode. In addition, the ATAT-tetrad was observed in the crystal
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bottom pose, which is consistent with the bottom binding trajectory of our free binding
simulations. Clearly, the lack of the crystal packing constraints led to these changes.
Therefore, the relaxation by MD simulations generated better solution reference structures
for our free binding simulations.

C

A

B

Figure 44. H-bond network indicating maximum number of H-bonds possible in G-tetrad
(A), ATAT-tetrad (B) and T-dyad (C) respectively.

Our free binding simulations found that BRACO19 binds to the same telomeric
DNA G-quadruplex structure in three different modes: Top stacking (11.9% total
population), bottom intercalation (51.1% total population), and in the groove (9.6% total
population). The bottom intercalation and top stacking mode resemble the BRACO19
binding pose in the crystal structure. Our MM-PBSA/MM-GBSA and trajectory analysis
show the bottom intercalation mode to be more stable than top stacking mode or groove
binding mode. The apo form of the G-quadruplex in the crystal (Figure 30E &F) is known
to have three G-tetrads whereas the top stacking and groove binding mode from the
simulations were observed to have three G-tetrads, one ATAT-tetrad and one T-dyad. In
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the ATAT-tetrad every adenine and thymine forms 6 H-bonds with adjacent thymine and
adenine respectively (Figure 44) and in T-dyad, the thymine bases share 2 H-bonds with
each other. The detailed analysis of number of H-bonds in each predefined layer is
illustrated in Figure 71. Interestingly, the direct alignment type of an intra-quadruplex
ATAT-tetrad observed in our simulation is different from the slipped alignment type of
ATAT-tetrad identified by the previous NMR study of d(GAGCAGGT) sequence in 1M
NaCl solution under which it forms a head-to-head dimeric quadruplex containing
sequentially stacked GCGC, GGGG and slipped ATAT tetrads.(Zhang et al., 2001) This
intra-quadruplex ATAT-tetrad is also different from the inter-quadruplex ATAT-tetrad that
was observed in the crystal structure 3CE5 (Figure 31), although both share the similar
geometry and H-bond pattern. Therefore, further experimental evidence is required to
prove our prediction of the direct intra-quadruplex ATAT-tetrad. In the groove binding
mode, T6 flipped out to facilitate BRACO19 insertion. A notable speculation in this study
is that the groove binding mode is likely to be an intermediate stage in the process of
achieving the final stable end stacking mode, which has been observed in our early study
of binding of RHPS4 to human telomeric G-quadruplex(Kelly Mulholland et al., 2017) and
in a study of binding of BRACO19 to a single stranded parallel telomeric G-quadruplex
(to be published).
The fore mentioned conformational differences between the apo and holo form of
the G-quadruplex (i.e. the bottom intercalation mode) in the crystal structure were partially
reproduced by the simulations. First, as to the flipping out of T6, T7 and A8 in the crystal
complex structure (Figure 37C and 37E), the flipping out of the latter two was observed in
the simulations (Figure 37C). Second, as to the formation of the first base layer by T1, A2
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and A14 in the crystal structure, this was observed in both bottom intercalation trajectories
(Figure 38). In addition, further optimization of the bottom intercalation was observed in
the simulation: while the T12 and T24 are not yet paired in the X-ray crystal structure
(Figure 31), this T-dyad was formed in the simulation. As a result, BRACO19 is
intercalated between the G-tetrad formed by residues 5, 11, 17 and 23 and the T-dyad by
residues 12 and 24. The intercalation between G-tetrad and T-dyad increased the ligand
binding energy to the G-quadruplex.
The planarity of BRACO19 central rings permits the compound to stack on top and
intercalate at the bottom of telomeric G-quadruplex. For this reason, planarity is a critical
feature to be considered in developing G-quadruplex specific ligands. A planar scaffold
not only increases the binding selectivity, but also boosts the intercalation thus increasing
overall binding affinity. These findings may aid future attempts at creating a promising
telomeric G-quadruplex stabilizer with large central rings.
The dihedral angles of the 3 G-tetrads in both stability simulation and free binding
simulations have low fluctuations and are consistent through the binding process. The
dihedral angles of the terminal layers, ATAT-tetrad and T-dyad demonstrated more
fluctuations. The torsion angle analysis indicated that the conformational changes are
characterized mainly by α, γ, ε and ζ and in some cases, changes in χ dihedral angle. And
the recent corrections (εζOL1, εζOL1and χOL4) in the AMBER OL15 DNA force field
appears to provide a more balanced dihedral angle sampling which contributed to a good
agreement to the experimental structures.
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3.6 Conclusions
Computational methods are getting more and more significant in drug discovery as
they provide detailed structural information. Molecular dynamics binding simulations,
MM-PBSA and MM-GBSA binding energy calculations were utilized in this study, to
characterize binding modes of BRACO19 to a telomeric DNA parallel G-quadruplex at
physiological solution conditions and validate the utilization of latest AMBER DNA force
field (OL15) with recent corrections βOL1, εζOL1 and χOL4 coupled with GAFF2 ligand
force field in studying G-quadruplex in complex with a ligand. Three binding modes have
been identified: top stacking, bottom intercalation and groove binding. Bottom
intercalation and top stacking resembles very well the binding pose in the X-ray solved
crystal structure of the same telomeric G-quadruplex with BRACO19. The groove binding
mode is likely to be an intermediate state leading to the end binding mode. A flip-insertion
mechanism was observed in the bottom intercalation mode, during which the flipping out
of the bases make space for ligand insertion, followed by the flipping back of the bases to
increase the stability of the complex. Formation of an intra-quadruplex ATAT-tetrad has
been observed for the first time. Torsion angle analysis indicated good sampling of dihedral
angles and a good agreement with the experimental structures.
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Chapter 4
Binding of BRACO19 to a Telomeric G-Quadruplex DNA Probed by All-Atom
Molecular Dynamics Simulations with Explicit Solvent
4.1 Abstract
High efficacy is displayed by the potently binding human telomeric DNA Gquadruplex drug, BRACO19, in inhibition of tumor cell growth. Although, the
improvement of its’ 62-fold preferential binding affinity towards DNA G-quadruplex over
DNA duplex remains to be a challenge. The crystal structure of BRACO19 in complex
with neither single-stranded telomeric DNA G-quadruplexes nor B-DNA duplex is
available yet. Consequently, the characteristic binding nature of BRACO19 and these DNA
forms remains elusive. In this study, the binding pathway of BRACO19 is characterized
by simulating 200 ns MD binding simulations with a free ligand (BRACO19) to a DNA
duplex and three different topological folds of the human telomeric DNA G-quadruplex
(parallel, antiparallel and hybrid). Groove binding mode was found to be the most stable
binding mode for the duplex and top stacking mode for parallel G-quadruplex, antiparallel
and hybrid G-quadruplexes. The non-existential binding selectivity of BRACO19 can be
accounted to the similar binding affinities of groove binding to both the duplex and the Gquadruplex. For that reason, a modification should be induced such that this prospective
ligand destabilizes binding to the duplex form but stabilizes the G-quadruplex binding.
Such modification can improve this mere 62-fold binding selectivity toward the Gquadruplex. Furthermore, the groove binding mode was found to be an intermediate stage
of the top stacking mode.
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4.2 Introduction
The formation of the first therapeutically important G-quadruplex was observed in
the single stranded overhang of human telomeric DNA.(J. Debray et al., 2009; Doluca,
Withers, & Filichev, 2013a) The single stranded 3’ overhang (100-200 nucleotides) is the
termini of the human telomeric DNA which contains numerous repeats of d(TTAGGG)
sequences and is capped by Shelterin complexes.(Chung et al., 2013c; de Lange, 2005a;
Moyzis et al., 1988a; Wright, Tesmer, Huffman, Levene, & Shay, 1997b) Shelterin
complexes provides protection against nuclease attacks, chromosomal end-to-end fusion
and gene erosion at cell divisions.(Palm & de Lange, 2008) After each cell replication, the
telomere truncates by 50-200 base pairs and when the telomere is exhausted and Hayflick
limit is reached, cell senescence and apoptosis are triggered.(Harley, Futcher, & Greider,
1990a; Zakian, 1995a).
In cancer cells, a reverse transcriptase called telomerase adds nucleotides to the
telomere thus immortalizing the cells. (Greider & Blackburn, 1989b; Moorhouse et al.,
2006a) Telomerase is found to be overexpressed in 80-85% of tumor cells. It can be
logically concluded that telomerase inhibition is a valid therapeutic approach in cancer
treatment. But the challenges with this approach are (i) there is a time delay in which the
telomere length needs to be established for the ultimate apoptosis trigger(Asai et al., 2003;
Harley et al., 1990a; Shay & Wright, 2006) and (ii) studies suggest an alternate mechanism
for telomerase maintenance might be activated upon telomerase inhibition.(Bechter, Zou,
Walker, Wright, & Shay, 2004; Dunham, Neumann, Fasching, & Reddel, 2000; Hu et al.,
2012) It has been reported that the telomere cannot be hybridized by telomerase when the
single stranded 3’ overhang folds into a G-quadruplex.(Zahler, Williamson, Cech, &
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Prescott, 1991a) Consequently, stabilizing the telomeric G-quadruplex adopted by
guanidine-rich single stranded 3’ overhang which will be perceived as DNA damage and
stimulates cell apoptosis. (Denchi & de Lange, 2007a; Doluca et al., 2013a)
G-quadruplexes can be formed from a single or double stranded DNA duplex. It
has been experimentally established that the telomeric sequences can fold into four
topologies in dilute solutions; hybrid [3+1] (PDB IDs: 2HY9 and 2JPZ), parallel (PDB ID:
1KF1), one 2-tetrad antiparallel and one 3- tetrad antiparallel (PDB ID: 143D) folds. And
this folding depend on sequence, ions and presence of small molecules.(Hänsel et al.,
2011a) Traditional studies suggest that the polymorphism is lost in 40% PEG or 50%
ethanol solutions, in other words dehydrated solutions, parallel stranded conformation
prevails. Concluding that parallel G-quadruplex is biologically relevant. Many studies were
reported to develop lead compounds targeting them. Hansel et al suggested that parallel Gquadruplex might not be the most prevalent form and other topologies need to be studied
to understand and design lead compounds with better binding affinities and
selectivity.(Hänsel et al., 2011a)
BRACO19, tri-substituted acridine shown in figure 30, was logically designed with
computer modelling by understanding the structural requirements of the parallel-stranded
G-quadruplex binding site.(Yang & Okamoto, 2010a) BRACO19 has been reported to
inhibit telomerase causing telomere shortening(Incles et al., 2004) and its experimental invivo activity has been reported (Table 110). It was also reported that BRACO19
demonstrated broad anti-viral activity by stabilizing the G-quadruplexes found in pro-viral
DNA.(Perrone et al., 2014) Lack of selectivity towards G-quadruplex over duplex DNA is
one of the reasons BRACO19 has never been approved.(Yang & Okamoto, 2010a) To
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achieve higher selectivity (in the order of 10 ), better understanding of characteristic
binding of BRACO19 with DNA G-quadruplex and duplex DNA is required.
The only available crystal structure with BRACO19 (PDB ID: 3CE5) is double
stranded with a parallel G-quadruplex arrangement. The G-quadruplex asymmetrically
interacts with the ligand via π–π interactions with the guanine bases, stacking the K+ inline. Computational studies reported that homologous variation of the side chains decreases
the binding affinity (Campbell, Parkinson, Reszka, & Neidle, 2008) although these studies
might be irrelevant as the telomeric overhang that folds into a G-quadruplex is single strand
DNA. It is also to be noted that not many studies could be found on other scaffolds i.e.,
anti-parallel and hybrid.
Debray et al synthesized and evaluated fused bis-pyrimidinoacridines, pentacyclic
analogs of BRACO19 in order to understand the interactions of these analogs with the Gquadruplex. The analogs were docked onto DNA G-quadruplex (PDB ID: 22AG), and
DNA-duplex (PDB ID: DS17) and parallel G-quadruplex with BRACO19 (PDB ID: 3CE5)
in the binding site.(Julien Debray et al., 2009) Xue et al synthesized and docked NeomycinPerylene conjugate onto the antiparallel G-quadruplex. Their docking data indicated that
perylene moiety stacked onto the DNA bases and the two neomycin units occupied two Gquadruplex grooves.(Xue, Ranjan, & Arya, 2011) Long et al introduced a peptidyl group
on benzo-furo-quinoline derivatives; and their combined experimental and molecular
docking data using parallel G-quadruplex suggest that the peptidyl group increased their
selectivity significantly towards telomeric DNA quadruplex over duplex DNA.(Long et al.,
2012) Alcaro et al identified and characterized novel G-quadruplex binders by dockingbased virtual screening using the three known folds of DNA-quadruplex; hybrid [3+1],
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parallel and antiparallel folds.(Alcaro et al., 2013) Their docking data showed that most of
the ligands stacked at the bottom of 1KF1 and 2HY9, but in the case of 143D and 2JPZ
most of the ligands docked laterally. Multiple computational methods including
pharmacophore modeling, shape-based modeling and docking were employed on DNA Gquadruplexes (PDB IDs: 3SC8, 3UYH, 3CE5 and 3R6R) and lead candidates with
promising potency were identified.(Kaserer et al., 2016) Nonetheless, it is well known that
the docking with a rigid receptor might lead to incorrect binding modes and poor docking
scores, therefore eliminating a prospective lead compound.(Mohan, Gibbs, Cummings,
Jaeger, & DesJarlais, 2005)
G-quadruplexes in complex with BRACO19 and various ligands have been widely
studied using molecular dynamic (MD) simulations. Moore et al conducted MD
simulations to investigate the structure-activity relationships of tri-substituted acridines
analogs (BRACO19 analogs) and a modelled 22mer parallel G-quadruplex.(Moore et al.,
2006b) Hou et al revealed H-bonds to be the major contributors for stability of the Gquadruplex and ligand-quadruplex complex by conducting stability simulations on Gquadruplex-ligand complexes involving BRACO19 and 5 other ligands, known for affinity
towards DNA G-quadruplex.(J. Q. Hou et al., 2010b) Dhamodharan et al advised endstacking to be the favored binding mode after docking bis-quinolinium and bis-pyridinium
derivatives of 1,8-naphthyridine onto antiparallel G-quadruplex and consequently,
conducting MD simulations. (Dhamodharan, Harikrishna, Jagadeeswaran, Halder, &
Pradeepkumar, 2012a) However, Jain et al reported that both end-stacking and groovebinding

were

favored

after

docking

dimeric

1,3-phenylene-bis(piperazinyl

benzimidazole)s to 22mer parallel G-quadruplex followed by MD simulations.(Jain, Paul,
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Maji, Muniyappa, & Bhattacharya, 2012b) Ungvarsky et al characterized the binding poses
of a novel set of BRACO19 derivatives to the human telomeric parallel G-quadruplex by
successfully employing docking and MD simulations.(Ungvarsky et al., 2014b) Zhou et al
attempted to understand the ligand unbinding from G-quadruplex using steered molecular
dynamics and umbrella simulations.(J. K. Zhou, Yang, & Sheu, 2015b). Recently
Diveshkumar et al conducted, by docking and MD simulation studies on various Gquadruplexes (PDB IDs: 2L7V, 2O3M, 1KF1, 143D, and 2MB3) and identified indolyl,
methylene-indanone scaffolds which demonstrate selectivity towards parallel promoter Gquadruplexes over telomeric DNA quadruplex or duplex DNA.(Diveshkumar et al., 2016b)
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A

B

C

D

Figure 45. Structure of human telomeric DNA duplex (A), human telomeric parallel DNA
quadruplex (PDB ID: 1KF1) (B), human telomeric antiparallel DNA quadruplex (PDB ID:
143D) (C), and human telomeric hybrid DNA quadruplex (PDB ID: 2HY9) (D). 5’ and 3’
of the DNA chain are indicated by a red and blue ball, respectively.
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In this study, the binding pathway of BRACO19 to parallel, anti-parallel, hybrid
DNA G-quadruplex and duplex DNA is characterized by conducting molecular dynamics
binding simulations. In this study, the binding pathway of BRACO19 to parallel, antiparallel, hybrid DNA G-quadruplex and duplex DNA is characterized by conducting
molecular dynamics binding simulations. MD free ligand binding simulations in which no
constraints are placed on the relative position of the ligand were utilized to probe the
binding pathway and mechanism of BRACO19 to the human telomeric parallel Gquadruplex DNA. Major binding poses, (top binding, end stacking, bottom binding and
groove binding) were identified and detailed binding pathways were characterized. The
dynamic and energetic properties of the three major binding modes were thoroughly
studied, providing vivid examples of induced-fit binding mechanism. The similar binding
energy of the groove binding pose to the duplex and the G-quadruplexes may be
responsible for the low selectivity of BRACO19. The binding pathway of BRACO19 to
various G-quadruplexes is characterized using torsion angle parameters. This analysis
indicated good sampling of dihedral angles and a good agreement with the experimental
structures.
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4.3 Methods
4.3.1 Simulation systems.

DNA Duplex + Unbound BRACO19

Anti-parallel DNA
Unbound BRACO19

Quadruplex

Parallel DNA G-Quadruplex + Unbound
BRACO19

+ Hybrid DNA Quadruplex + Unbound
BRACO19

Figure 46. Initial configuration of the simulation systems. 5’ and 3’ of the telomeric DNA
are indicated by a red and blue ball, respectively and the K+ ions are represented in yellow.

A total of 4 DNA-ligand systems were constructed: B-DNA duplex structure of
d([GC]10)2, X-ray crystal structure of the parallel telomeric DNA G-quadruplex, NMR
solved anti-parallel telomeric DNA G-quadruplex and NMR-solved (3+1) hybrid telomeric
DNA G-quadruplex (figure 46). One B-DNA duplex structure of d([GC]10)2, built using
Maestro program, one X-ray solved human telomeric parallel G-quadruplex and two NMR
solved human telomeric G-quadruplex structure were each used to construct four unbound
DNA-ligand systems with a BRACO19 molecule that was 10 Å away from the DNA
(Figure 46). A water box of truncated octahedron with 10 Å water buffer was used to
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solvate the unbound system. And it was neutralized by K+. The DNA structures were
represented by a refined version of the AMBER DNA OL15 (i.e. parm99bsc0(Pérez et al.,
2007) +χOL4 (Krepl et al., 2012b)+ ε/ζOL1(Zgarbova et al., 2013)+ βOL1(Zgarbova et al.,
2015) updates), water was represented by TIP3P model(Jorgensen, Chandrasekhar,
Madura, Impey, & Klein, 1983c) and the K+ ions were represented by the K+ model
developed by Cheatham group.(Joung & Cheatham, 2008b) The standard AMBER
protocol was used to obtain the force field for the BRACO19 molecule: after the geometry
optimization of the BRACO19 at the HF/6-31G* level, the molecular electrostatic potential
(MEP) of the BRACO19 molecule was calculated at the same theory level; then the partial
charges of BRACO19 atoms was determined by MEP using Restrained Electrostatic
Potential/RESP method with two stage fitting;(Bayly, Cieplak, Cornell, & Kollman,
1993a) and the AMBER GAFF2(Case et al., 2016) force field provided the rest of the force
field parameters. The nucleic acid simulations have been widely practiced in AMBER
DNA force fields.(Cosconati et al., 2010; Fadrna et al., 2009; Lavery et al., 2010; A.
Mukherjee, Lavery, Bagchi, & Hynes, 2008) In our studies, the binding pathway of
doxorubicin(Lei, Wang, & Wu, 2012b) and telomestatin(K. Mulholland & Wu, 2016), anticancer drugs, to the B-DNA fragment(Lei et al., 2012b) and to the human telomeric hybrid
G-quadruplex(K. Mulholland & Wu, 2016), respectively have been simulated.
4.3.2 Simulation protocols. The ten production runs for all systems were
conducted using the AMBER 16 simulation package.(Case et al., 2016) The detailed
protocol followed our previous studies.(Lei et al., 2012b; K. Mulholland & Wu, 2016)
After minimizing the energy, the Maxwell-Boltzmann distribution was followed in using
different random seeds to assign different initial velocities to the atoms of the system.
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Better sampling of binding poses and pathway was enabled by multiple independent
simulations. To equilibrate the system density, a 1.0 µs production run at 300 K which
included a short 1.0 ns MD simulation in the NPT ensemble mode (constant pressure and
temperature), where the DNA and ligand were subjected to Cartesian restraints (1.0
kcal/mol/Å), and 200.0 ns (500 ns for one trajectory of parallel G-quadruplex) MD
simulation in the NVT ensemble mode (constant volume and temperature). All bonds
connecting hydrogen atoms were constrained by SHAKE(Ryckaert, Ciccotti, & Berendsen,
1977b) which enabled a 2.0 fs time step in the simulations. Long-range electrostatic
interactions under periodic boundary conditions were treated using the particle-mesh
Ewald method(Essmann et al., 1995b) (the fourth order of the B-spline charge
interpolation, charge grid spacing of ~1.0 Å; and direct sum tolerance of 10 –5). The cutoff
distance for short-range non-bonded interactions was 10 Å, with the long-range van der
Waals interactions based on a uniform density approximation. To reduce the computation
cost, a two-stage RESPA approach(Procacci & Berne, 1994b) was used to calculate nonbonded forces where the short range forces were updated every step and the long range
forces were updated every two steps. The Langevin thermostat with a coupling constant of
2.0 ps was used to control the temperature. The trajectories were saved at 50.0 ps intervals
for analysis.
4.3.3 Convergence of simulations. The initial structure was used as a reference to
calculate the root mean square deviation (RMSD) of DNA backbone. The stability of the
DNA structures was indicated by the flat and small RMSDs (Figure 62, 64, 66 and 68). An
atom-to-atom distance cutoff of 3.0 Å was used to calculate atom contacts between the
DNA structure and the BRACO19. The stable contact number indicated the steady state of
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the simulation systems (Figure 63, 65, 67 and 69). A complex with the number of atom
contacts greater than 10 was defined as a stable complex.
4.3.4 Binding mode identification. Accounting to the stability of the DNA
backbone in the binding process, the DNA backbone of the stable complexes was aligned
by a least square fitting. Daura algorithm (Daura et al., 1999b) was used to cluster the
aligned complexes into different structural families based on the 2 Å pair-wise RMSD
cutoff of the BRACO19 only without ligand fit. The centroid structure was defined as a
structure with the largest number of neighbors in the structural family. And this structural
family was represented by this centroid structure. Based on visual inspection, superfamilies corresponding to major binding modes were formed by merging the centroid
structures.
4.3.5 Order parameters. The DNA-drug binding process was characterized by
using five order parameters: hydrogen bond analysis, drug-base dihedral angle, ligand
RMSD, center-to-center and K+-K+ distance (R) and MM-GBSA binding energy (ΔE). A
hydrogen bond was defined by 3.5Å distance cutoff between H-bond donor and H-bond
acceptor and 120° donor-H-acceptor angle cutoff. The hydrogen bonds were calculated for
the top/first, middle/second and bottom/third base layers. For the duplex, the three base
layers were defined based on the drug insertion position. For the three G-quadruplexes, the
three G-tetrads were defined so that 5’ is close to the first G-tetrad. The dihedral angle
between the plane of the stable G-tetrad layer of the DNA that is close to drug binding site
and the BRACO19’s ring plane was defined as the dihedral angle. After aligning the DNA,
the ligand RMSD was calculated with reference to the first frame of the trajectory. The
length from the DNA center to the drug molecule center was defined as the center-to-center
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distance (R). The distance between the K+ ions present in the DNA G-quadruplex was
defined as K+-K+ distance. The energetics of the bound complexes were analyzed using
MM-GBSA(P. A. Kollman et al., 2000) (Molecular Mechanics Generalized Born-Surface
Area) module in the AMBER package (GB1 model with salt concentration of 0.2 M,
mBondi radii set, and surface tension of 0.0072 kcal/Å2) to avoid the large energy
fluctuation of the explicit solvent.
It was reported that even when considering the relative solvation free energy, good
predictions can be made for charged molecules by the GB models on the hydration free
energy.(Kongsted, Soderhjelm, & Ryde, 2009a) Under this assumption, in this study, ions
were removed from charged DNA systems. This was already validated in our previous
study, in which this MMGBSA protocol successfully assessed the binding energy of
doxorubicin, an anti-cancer drug, to a B-DNA fragment (d(CGATCG)2).(Lei, Wang, &
Wu, 2012c) Under comparable entropic terms, the relative binding free energy estimated
by the MMGBSA binding energies can be used to rank drugs or their binding poses if a
single molecule is considered.(Kongsted, Soderhjelm, & Ryde, 2009b) It has been
established by systematic benchmarking studies up to 1864 crystal complexes that ranking
of the ligand binding affinity can be achieved by relative MM-GBSA binding energy
calculations.(Hou, Wang, Li, & Wang, 2010, 2011; P. Kollman et al., 2000; Sun, Li, Tian,
Xub, & Hou, 2014; Xu, Sun, Li, Wang, & Hou, 2013) The standard backbone dihedral
angles (α, β, γ, δ, ε and ζ) around the covalent bonds of the deoxyribose and χ about the
glycosidic bond were defined (figure 34) to characterize the conformational changes.
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D) Hybrid Quadruplex

C) Antiparallel
Quadruplex

B) Parallel
Quadruplex

A) DNA Duplex

4.4 Results

Figure 47. Simulated structures of human telomeric DNA duplex (A), human telomeric
parallel DNA quadruplex (PDB ID: 1KF1) (B), human telomeric antiparallel DNA
quadruplex (PDB ID: 143D) (C), and human telomeric hybrid DNA quadruplex (PDB ID:
2HY9) (D) in complex with BRACO19. A-D: Top pose (left), Bottom (middle) and groove
(right) 5’ and 3’ of the telomeric DNA are indicated by a red and blue ball, respectively
and the K+ ions are represented in yellow.
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4.4.1 Multiple drug binding modes were observed in binding simulations.
Starting from an unbound state, ten production runs for all four systems were simulated.
The convergence of the binding simulations was confirmed (see the method section). The
last snapshots of all the simulated trajectories of duplex are listed in figure 48 and they
indicate the stability of the structures; the base pairing was maintained.
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Front View

Description

Front View

Description

Run 01 (Groove)

Run 06 (Groove)

Run 02 (Groove)

Run 07 (Groove)

Run 03 (Groove)

Run 08 (Top)

Run 04 (Bottom)

Run 09 (Groove)

Run 05 (Groove)

Run 10 (Groove)

Figure 48. Last snapshots of 10 DNA duplex and BRACO19 simulations. 5’ and 3’ of the
telomeric DNA are indicated by a red and blue ball.
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And the last snapshots of all the simulated trajectories of G-quadruplexes are listed
in figure 49, 50 and 51. They indicate the stability of the structures; the G-tetrads were
maintained and the K+ ions retained their position in almost all the trajectories. It is to be
noted that in figure 49, run 07 and 09 the K+ ion moved out of the quadruplex and this
disrupted the G-quadruplex. This will be discussed later.

Front View
Description
Run 01 (Top)

Front View
Description
Run 06 (Top)

Run 02 (Top)

Run 07 (Groove)

Run 03 (Top)

Run 08 (Top)

Run 04 (Top)

Run 09 (Top)

Figure 49. Last snapshots of 10 parallel telomeric DNA G-quadruplex and BRACO19
simulations. 5’ and 3’ of the telomeric DNA G-quadruplex are indicated by a red and blue
ball, respectively.
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Run 05 (Groove)

Run 10 (Groove)

Figure 49 (continued)

Front View
Description
Run 01 (Side)

Front View
Description
Run 06 (Side groove)

Run 02 (Top)

Run 07 (Top)

Run 03 (Side groove)

Run 08(Side groove)

Figure 50. Last snapshots of 10 anti-parallel telomeric DNA G-quadruplex and BRACO19
simulations. 5’ and 3’ of the telomeric DNA G-quadruplex are indicated by a red and blue
ball, respectively.
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Run 04 (Top)

Run 09 (Top)

Run 05 (Side groove)

Run 10 (Top)

Figure 50 (continued)

Front View
Description
Run 01 (Top)

Front View
Description
Run 06 (Bottom)

Run 02 (Bottom)

Run 07 (Top)

Figure 51. Last snapshots of 10 hybrid telomeric DNA G-quadruplex and BRACO19
simulations. 5’ and 3’ of the telomeric DNA G-quadruplex are indicated by a red and blue
ball, respectively.
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Run 03 (Side)

Run 08 (Side)

Run 04 (Groove)

Run 09 (Top)

Run 05 (Groove)

Run 10 (Side)

Figure 51 (continued)

Multiple binding sites were observed in the ten duplex DNA-BRACO19
trajectories. The clustering analysis described in the methods section was employed to
categorize the stable complexes, extracted from these trajectories, into structural families.
By setting a threshold of 1% population, 14 structural families of complexes were
identified. These 8 structural families were further merged into three binding modes:
groove binding, top stacking and bottom stacking. Binding to the groove of the duplex
accounted for 81% of the total population. Additionally, end stacking to the top of the
duplex accounted for 4% and end stacking to the bottom of the duplex made up 2% of the
total population. Two binding modes were observed in the ten parallel G-quadruplex DNA-
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BRACO19 trajectories. The same clustering analysis was employed to categorize the stable
complexes, extracted from these trajectories, into 10 structural families. Two binding
modes were observed: top stacking and groove binding. Top stacking to the parallel Gquadruplex DNA accounted for 56% and groove binding for 41% of the total population.
Multiple binding sites were observed in the ten antiparallel G-quadruplex DNA-BRACO19
trajectories. The same clustering analysis was employed to categorize the stable complexes,
extracted from these trajectories, into 9 structural families. Three binding modes were
observed: top, bottom and groove binding. Bottom binding to the antiparallel G-quadruplex
DNA accounted for 47%, top binding for 33% and groove binding for 21% of the total
population. Multiple binding sites were observed in the ten hybrid G-quadruplex DNABRACO19 trajectories. The same clustering analysis was employed to categorize the stable
complexes, extracted from these trajectories, into 12 structural families. Three binding
modes were observed: top, groove and bottom binding. Groove binding to the hybrid Gquadruplex DNA accounted for 74%, Top binding for 19%, and bottom binding for 9% of
the total population.
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4.4.2 VDW interaction contributes most to the total binding energy, ranking
the binding poses for each DNA-ligand system.

Table 114
MM-GBSA binding energy (kcal/mol) of BRACO19 to human telomeric DNA duplex and
Quadruplexes.
11
14
ΔEGBEL 12ΔECON 13
ΔΔET
9
10
System Pose
ΔEVDW
ΔESUR
ΔETOT
15

TS
DNA 16
BB
Duplex 17
GB
Parallel TS
Quad
GB
TS
AntiParallel BB
Quad
GB
TS
Hybrid
BB
Quad
GB

-28.9±4.0
-28.4±4.1
-57.9±9.5
-63.1±5.7
-37.0±6.4
-41.5±11.4
-29.1±9.0
-43.0±6.0
-44.2±11.4
-25.7±5.8
-40.5±6.6

-2.3±0.5
-2.2±0.5
-5.2±0.7
-5.2±0.6
-3.1±0.4
-4.0±1.1
-2.5±0.8
-3.4±0.5
-4.3±1.0
-2.8±0.7
-4.0±0.5

E

F

-5.2±3.1
-4.8±3.2
-3.9±4.5
-1.9±4.4
-8.9±4.5
-8.5±4.3
-9.2±3.0
-7.5±2.6
-12.1±5.0
-16.3±6.0
-14.9±5.2

2.7±1.2
0.8±3.8
5.2±2.8
7.9±5.2
11.4±4.5
0.1±4.6
-2.1±4.4
10.9±2.3
20.0±9.2
15.8±8.5
23.7±3.6

T

-33.7±5.3
-34.6±5.7
-61.7±8.0
-62.3±4.5
-37.6±7.2
-53.9±5.8
-42.8±4.1
-43.1±7.2
-40.5±5.4
-29±12.9
-35.7±5.1

28.6
27.7
0.6
0
24.7
8.4
19.5
19.2
21.8
33.3
26.6

MM-GBSA binding energy calculations were carried out as depicted in methods
section to examine the relative binding affinities major binding modes of BRACO19 with
respect to DNA and summarized in Table 114. Of the three binding modes of BRACO19
to the DNA duplex, the best binding energy was in the groove binding mode (-69.5±8.0
kcal/mol), followed by the top stacking mode (-34.8±5.3 kcal/mol).

9

Change of van der Waals energy in gas phase upon complex formation
Change of surface area term change upon complex formation
11
Change of GBELE generalized Born term + gas phase electrostatic energy upon complex formation
12
Change of conformational energy upon complex formation
13
Change of total potential energy in water upon complex formation (VDW+SUR+GBELE+CONF)
14
Change in binding energy with a reference to top stacking parallel G-quadruplex
15
Top Stacking
16
Bottom Binding
17
Groove Binding
10
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VDW packing responsible for the VDW energy contribution governed the binding
energy order of the three modes. The VDW contribution in the groove mode (-59.8±5.5
kcal/mol) points out that in the groove binding mode, one side of BRACO19 was still
exposed to solvent. BRACO19 bound to parallel G-quadruplex DNA in two binding poses.
Top stacking (-72.1±4.5kcal/mol) was the most, making the groove binding (-40.3±7.2
kcal/mol) being the least stable of the two. BRACO19 bound to antiparallel G-quadruplex
DNA in three binding poses. Top binding (-60.9±5.8 kcal/mol) was the most stable of the
three with groove binding exhibiting a binding energy of only -57.2±7.2kcal/mol. Bottom
binding was the lowest with a binding energy of -45.2±4.1kcal/mol. BRACO19 bound to
hybrid G-quadruplex DNA in three binding poses as well. Top binding (-63.4±5.4
kcal/mol) was the most stable of the three, followed by groove binding (-56.8±5.1
kcal/mol) and bottom binding (-55.3±12.9 kcal/mol).
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4.4.3 BRACO19 binds to the duplex DNA, without inducing structural
changes.

0 ns

3 ns

4 ns

5 ns

6 ns

7 ns

8 ns

14 ns

Figure 52. A representative groove binding trajectory of the DNA duplex. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue
ball, respectively. Bottom: An order parameter plot depicting number of hydrogen bonds
present in first base pair (green), second base pair (red) and third base pair (blue) layers of
the DNA structure (figure 45), the drug-base dihedral angle, receptor (red) and ligand
(black) RMSD relative to the original crystal pose, center-to-center distance and MMGBSA binding energy (ΔE) (cf. methods section for definition).
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The representative trajectory for the groove binding of BRACO19 to the duplex
DNA are characterized in Figure 52. In all ten binding trajectories, the DNA showed low
structural fluctuation with RMSD of 2.4 Å (Figure 62) and the hydrogen bonds between
the base pairs were maintained. In the representative trajectory of BRACO19 binding to
the groove of the human telomeric duplex DNA in figure 52, an initial interaction was
observed as early as 3 ns and the final binding pose was achieved at an astounding 14 ns
and was maintained throughout the remainder of the trajectory. The limited fluctuation in
the five order parameters explains the limited structural dynamics. The other representative
trajectories of BRACO19 top stacking, groove binding, bottom stacking also exhibited
rapid binding and limited dynamics, binding to the complex at 8 ns and 19 ns respectively.
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4.4.4 Groove binding might be an intermediate state for the top stacking mode

0 ns

3 ns

19 ns

26 ns

56 ns

102 ns

376 ns

463 ns

Figure 53. A representative top stacking trajectory of the parallel G-quadruplex. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue
ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are
indicated in red and the K+ ions are represented in yellow. Bottom: An order parameter
plot depicting number of hydrogen bonds present in first G4 (green), second G4 (red) and
third G4 (blue) layers of the DNA structure (Figure 45), the drug-base dihedral angle,
receptor (red) and ligand (black) RMSD relative to the original crystal pose, center-tocenter distance (R/black) and K+-K+ distance (R/red) and MM-GBSA binding energy (ΔE)
(cf. methods section for definition).
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The representative trajectory for the top stacking mode of BRACO19 to the parallel
human telomeric G-quadruplex DNA are characterized in figure 53. In all ten binding
trajectories, the DNA showed low structural fluctuation with RMSD of 2.4 Å (Figure 64)
and the hydrogen bonds in the three G-tetrads were maintained. In the representative
trajectory of BRACO19 binding to the top of the human telomeric parallel G-quadruplex
DNA in figure 53, an initial interaction to the complex at 8 ns and attaining the stable
groove binding pose at 19 ns. However, on further simulation to 500 ns, at exactly 463 ns
BRACO19 was stacked on top of the parallel G-quadruplex. It can be inferred that groove
binding is an intermediate state for top stacking mode. This further simulation also showed
that the potassium ion from the G-quadruplex moved out followed by the disruption of the
third G-tetrad layer of the G- quadruplex inferring that the K+ ions are essential for the
stability of the G-quadruplex. The binding energy for top stacking fluctuated between -60
and -75 kcal/mol while bottom stacking varied between -35 and -45 kcal/mol after attaining
the steady binding pose.
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Figure 54. Comparison for the backbone torsion angles of residue T6 between the free
ligand binding simulation (red) of the top stacking mode of the parallel G-quadruplex and
the stability simulation of the crystal structure (black) of the parallel G-quadruplex. Top:
Time series, Bottom: Histograms.
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Dihedral angles of all DNA bases in the simulated parallel G-quadruplex were
analyzed. The dihedral angles of the G-tetrads in free ligand binding simulations indicate
low fluctuations and are consistent through the binding process. Major fluctuations were
observed in the terminal residues, T6 in particular is discussed here as it demonstrates
highest fluctuation. T6 flipped out at 15 ns and flipped back at 45 ns, flipped out at 69 ns
and flipped in at 100 ns and it finally flipped out at 114 ns and remained same throughout
the rest of the trajectory. This flipping out of the base is mainly characterized by α, β, γ and
χ (figure 54).
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4.4.5 BRACO19 binds to the anti-parallel G-Quadruplex, without inducing
structural changes.

0 ns

5 ns

8 ns

13 ns

31 ns

42 ns

63 ns

199 ns

Figure 55. A representative top stacking trajectory of the anti-parallel G-quadruplex. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue
ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are
indicated in red and the K+ ions are represented in yellow. Bottom: An order parameter
plot depicting number of hydrogen bonds present in first (red), second G4 (cyan), third G4
(blue), fourth G4 (black) and fifth (green) layers of the DNA structure (Figure 45), the
drug-base dihedral angle, receptor (red) and ligand (black) RMSD relative to the original
crystal pose, center-to-center distance (R/black) and K+-K+ distance (R/red) and MMGBSA binding energy (ΔE) (cf. methods section for definition).
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Figure 56. Comparison for the backbone torsion angles of residue T05 between the free
ligand binding simulation (red) of the top stacking trajectory of the anti-parallel Gquadruplex and the stability simulation of the crystal structure (black) of the anti-parallel
G-quadruplex. Top: Time series, Bottom: Histograms.
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The representative trajectory for the top stacking mode of BRACO19 to the
antiparallel human telomeric G-quadruplex DNA are characterized in figure 55. In all ten
binding trajectories, the DNA showed high structural fluctuation in four trajectories with
RMSD of 3.2 Å (Figure 66), the hydrogen bonds in the three G-tetrads were maintained
and the distance between K+ ions remained stable in all trajectories. The representative
trajectories of top stacking of BRACO19 with the human telomeric antiparallel Gquadruplex DNA, showed an initial interaction at an early 5 ns and the final binding pose
was achieved at an astonishing 42 ns and was maintained throughout the rest of the
trajectory. The limited structural dynamics was explained by the limited fluctuation in the
five order parameters. The representative trajectories of the groove binding and bottom
binding are similar to the top binding trajectory with a rapid binding and limited fluctuation
of order parameters. Early interaction at 1 and 5 ns respectively and attainment of final
binding pose by 16 and 55 ns respectively. The other representative trajectories of
BRACO19 top stacking, groove binding and bottom stacking also exhibited rapid binding
and limited dynamics, binding to the complex at 19, 5 and 2 ns respectively and attaining
the final binding pose at 117, 143 and 107 ns respectively and maintained it throughout the
rest of the trajectories. The binding energy for top stacking and groove binding fluctuated
between -55 and -65 kcal/mol while bottom stacking varied between -40 and -50 kcal/mol
after attaining the steady binding pose.
Dihedral angles of all DNA bases in the simulated anti-parallel G-quadruplex were
analyzed. The dihedral angles of the G-tetrads in free ligand binding simulations indicate
low fluctuations and are consistent through the binding process. Major fluctuations were
observed in the terminal residues, T5 in particular is discussed here as it demonstrates
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highest fluctuation. Through the binding process BRACO19 majorly interacted with T5, it
opened up as BRACO19 approached and at 29 ns, flipped out to let BRACO19 in, flipped
back at 40 ns and it stayed open afterward while interacting with BRACO19. This flipping
out of the base is mainly characterized by ε and ζ (figure 56).
4.4.6 BRACO19 binds to the hybrid telomeric G-Quadruplex DNA, without
inducing structural fluctuation. The representative trajectory for the top stacking of
BRACO19 with respect to the hybrid human telomeric G-quadruplex DNA are
characterized in figure 57. In all ten binding trajectories, the DNA showed high structural
fluctuation in five trajectories with RMSD of 2.9 Å (Figure 68), the hydrogen bonds in the
three G-tetrads were maintained and the distance between K+ ions remained stable in all
trajectories. The representative trajectory of BRACO19 top stacking onto the hybrid Gquadruplex DNA showed an initial interaction at 3 ns and the final binding pose was
attained as early as 30 ns and was maintained throughout the rest of the trajectory. The
limited structural dynamics was explained by the limited fluctuation in the five order
parameters. The representative trajectories of the groove binding and bottom binding are
similar to the top binding trajectory with a rapid binding and limited fluctuation of order
parameters. Early interaction at 2 and 9 ns respectively and final binding pose was attained
by 13 and 51 ns respectively. The other representative trajectories of BRACO19 top
stacking, groove binding and bottom stacking also exhibited rapid binding and limited
dynamics. The binding energy for all binding modes varied between -55 and -65 kcal/mol
after attaining the steady binding pose.

230
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4 ns
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13 ns

27 ns

30 ns

199 ns

Figure 57. A representative top binding trajectory of the hybrid G-quadruplex. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue
ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are
indicated in red and the K+ ions are represented in yellow. Bottom: An order parameter
plot depicting number of hydrogen bonds present in first (red), second G4 (cyan), third G4
(blue), fourth G4 (black) and fifth (green) layers of the DNA structure (Figure 45), the
drug-base dihedral angle, receptor (red) and ligand (black) RMSD relative to the original
crystal pose, center-to-center distance (R/black) and K+-K+ distance (R/red) and MMGBSA binding energy (ΔE) (cf. methods section for definition).
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Figure 58. Comparison for the backbone torsion angles of residue T8 between the free
ligand binding simulation (red) of the top binding trajectory of the hybrid G-quadruplex
and the stability simulation of the crystal structure (black) of the hybrid G-quadruplex.
Top: Time series, Bottom: Histograms.
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Dihedral angles of all DNA bases in the simulated hybrid G-quadruplex were
analyzed. The dihedral angles of the G-tetrads in free ligand binding simulations indicate
low fluctuations and are consistent through the binding process. Major fluctuations were
observed in the terminal residues, T8 in particular is discussed here as it demonstrates
highest fluctuation. T8 flipped out upon simulation and remained flipped through the rest
of the simulation except for a few ns after 38 ns and 143 ns. This flipping out of the base
is mainly characterized by α, δ, ε and ζ (figure 58).
4.5 Discussion
After the recent discovery of the greater existence of G-quadruplex in malignant
tumors than in normal tissues interest in G-quadruplex DNA as a promising target for
cancer therapeutics has increased. BRACO19, one of the most effective G-quadruplex
binding ligands, is a promising anticancer drug candidate, yet its low preferential binding
affinity (about ~62-fold) to the telomeric single-stranded G-quadruplex DNA over duplex
DNA remains to be enhanced. For better molecular insights, the binding of BRACO19 to
a duplex 20mer DNA (d([GC]10)2) and to the parallel, antiparallel and hybrid telomeric Gquadruplexes was investigated in this study using binding molecular dynamics simulations
with a free ligand.
Out of various binding modes for each system, the MM-GBSA binding energy
calculations showed that the most stable binding pose was the groove binding mode for the
duplex and the top stacking mode for the parallel G-quadruplex, the antiparallel Gquadruplex and the hybrid G-quadruplex (figure 45). The order of the relative binding
energy of BRACO19 in these most stable poses are as follows: -72.1±4.5 kcal/mol; the top
stacking to the parallel G-quadruplex (ΔΔE=0 kcal/mol) > -69.5±8.0 kcal/mol; the groove
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binding to the duplex DNA (2.6 kcal/mol) > -63.4±5.4 kcal/mol; the top stacking to the
hybrid G-quadruplex (8.7 kcal/mol) > -60.9±5.8 kcal/mol; the top stacking to antiparallel
G-quadruplex (11.2 kcal/mol).

Figure 59. (A) The experimental binding mode (PDB ID: 3CE5) of double stranded
parallel telomeric DNA G-quadruplex (B) Major binding pose of simulated single stranded
parallel telomeric DNA G-quadruplex.

The combination of the long time (1 μs) stability and the large magnitude of these
binding energies suggests an enthalpy driven binding is likely and the contribution of
entropy to the binding free energy to be of minor importance. Analysis by breaking down
the binding energy indicated that the VDW term makes the biggest contribution to the total
binding energy (Table 114). This indication suggests introducing target or drug specific
packing optimization as a prospect for further stabilization of the G-quadruplex. If these
binding modes have comparable entropic energies and the parallel G-quadruplex is the
major telomeric G-quadruplex species, then our relative binding energy signifies that
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BRACO19 binds preferentially to the telomeric G-quadruplexes than to the DNA duplex.
This qualitatively explains the experimental observation of preferential binding affinity
difference of BRACO19 on the two DNA forms. The emphasis is being directed to the fact
that the binding energies of the groove binding mode of the duplex and top stacking mode
of the G-quadruplex are comparable. This rationalizes the lack of binding selectivity of
BRACO19 to the two DNA forms. For that reason, it can be suggested that a ligand
modification that destabilizes the duplex groove binding mode but stabilizes the Gquadruplex top stacking mode will enhances the binding selectivity of the ligand. For
example, adding a planar ring fragment to the acridine would facilitate the top stacking
rather than groove binding and increase the van deer Waals interactions there for increasing
selectivity and binding affinity of the prospective drug towards the G-quadruplex. This
suggestion is consistent with the original SAR data in the development of BRACO19 from
prototype BSU6048 in which the addition of the ring at position 9 (makings of BRACO19)
increased the drug selectivity from 10-fold to 62 fold

towards human telomeric G-

quadruplexes over duplex DNA. (Harrison, Gowan, Kelland, & Neidle, 1999; White et al.,
2007; Yang & Okamoto, 2010a) And it is also to be noted that the sidechains on 3 and 6
contribute to the groove binding of both DNA duplex and G-quadruplex which could be
the reason behind low selectivity. So, suggestions can be made to reduce the length of these
side chains. These side chains exist in protonated form at physiological pH however, Table
114 indicates that the contribution of electrostatic interactions to the binding affinity is very
low and therefore modifications can be suggested to the substituents at 3 rd and 6th position
of the acridine. Modifications such as loss of positive charge which would increase the
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hydrophobicity which could in fact increase the van der Waals interactions and reduction
of the length of the side chains.
The most stable binding mode of BRACO19 to the DNA duplex is the groove
binding and the single stranded G-quadruplexes is top stacking mode, which is evidently
similar to the binding pose in the only X-ray solved crystal structure of a double stranded
G-quadruplex in complex of BRACO19 (Figure 70). The plane of BRACO19 is parallel
to the plane of G-tetrads. However, molecular details are different. In the groove binding
mode of duplex and the top stacking mode of parallel G-quadruplex, antiparallel and hybrid
G-quadruplex only one side of BRACO19 molecule interacted with the DNA. Lastly, the
groove binding mode was observed to be an intermediate stage of top stacking mode. The
dihedral angles of the 3 G-tetrads in free ligand binding simulations indicate low
fluctuations and are consistent through the binding process. The torsion angle analysis
indicated that the conformational changes are characterized mainly by α, β, γ, ε, and ζ and
in some cases changes in χ dihedral angle. Significant overlap between in the histogram of
free ligand binding simulation and crystal pose simulation indicate good prediction of the
torsion angle from MD simulation.
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4.6 Conclusion
The detailed structural knowledge of the intramolecular human telomeric G-quadruplexes
in complex with a ligand is required for the rational design of human telomeric Gquadruplex binding drugs. In this study, molecular dynamics binding simulations were
used to probe and understand the binding nature of BRACO19, a potent human telomeric
G-quadruplex drug, to a B-DNA duplex and the three scaffolds of a single stranded human
telomeric G-quadruplex. The most stable binding mode indicated by the MM-GBSA
binding energy analysis for the duplex DNA is the groove binding mode and top stacking
for parallel G-quadruplex, antiparallel and hybrid G-quadruplexes. The similar binding
affinity of BRACO19’s groove binding mode with respect to both the duplex and the Gquadruplexes explains its lack of preferential binding selectivity. Therefore, a ligand
modification that destabilizes the duplex groove binding mode but stabilizes the Gquadruplex top stacking mode will improve the binding selectivity of the ligand. Our study
presents a successful example of the ability of molecular dynamic simulations with the
latest AMBER force field to facilitate detailed structural and dynamic information which
will further decipher the binding nature of DNA ligands.
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Publications Note
The study illustrated in Chapter 2, CADD in Boron therapeutics is under
preparation for publication
The study illustrated in Chapter 3, probing the binding mechanism of BRACO19
and human telomeric DNA G-quadruplex is accepted for publication by Journal of
Chemical Information and Modelling
The study illustrated in Chapter 4, Binding of BRACO19 to a Telomeric GQuadruplex DNA Probed by All-Atom Molecular Dynamics Simulations with Explicit
Solvent is under preparation for submission to Physical Chemistry and Chemical Physics.
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Appendix A
RMSD and Contact Plots from Chapter 3

Figure 60. RMSD plot for each trajectory of parallel DNA G-quadruplex and BRACO19
system in ten runs
264

Figure 61. The contact number between parallel DNA G-quadruplex and BRACO19 for
each trajectory in ten runs.
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Appendix B
RMSD and Contact Plots from Chapter 4

Figure 62. RMSD plot for each trajectory of DNA duplex and BRACO19 system in ten
runs
266

Figure 63. The contact number between DNA duplex and BRACO19 for each trajectory
in ten runs.
267

Figure 64. RMSD plot for each trajectory of parallel DNA G-quadruplex and BRACO19
system in ten runs
268

Figure 65. The contact number between parallel DNA G-quadruplex and BRACO19 for
each trajectory in ten runs.
269

Figure 66. RMSD plot for each trajectory of anti-parallel DNA G-quadruplex and
BRACO19 system in ten runs
270

Figure 67. The contact number between anti-parallel DNA G-quadruplex and BRACO19
for each trajectory in ten runs.
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Figure 68. RMSD plot for each trajectory of hybrid DNA G-quadruplex and BRACO19
system in ten runs
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Figure 69. The contact number between hybrid DNA G-quadruplex and BRACO19 for
each trajectory in ten runs.
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Appendix C
2D Interactions and H-bond Network from Chapter 3

2D interactions with expanded
interacting residues

(B) MD Relaxed Crystal Bottom Pose

(A) Crystal Bottom Pose

2D interactions

Figure 70. 2D ligand-DNA interactions of BRACO19 in complex structures of (A) crystal
bottom pose, (B) MD relaxed crystal bottom pose, (C) bottom binding pose from free
binding simulations, (D) crystal top binding pose, (E) MD relaxed crystal top pose (F) top
binding pose from free binding simulations and (G) groove binding pose from free binding
simulations.
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2D interactions with expanded
interacting residues

(D) Crystal top binding Pose

(C) Free MD bottom Binding Pose

2D interactions

Figure 70 (continued)
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2D interactions with expanded
interacting residues

(F) Free MD top Binding Pose

(E) MD Relaxed Crystal top Pose

2D interactions

Figure 70 (continued)
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2D interactions with expanded
interacting residues

(G) Free MD Groove Binding Pose

2D interactions

Figure 70 (continued)
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H-bonds

AT-tetrad

G-tetrad (1)

T-dyad

(A)
X – Ray
Bottom Pose

(B)
MD Relaxed
Crystal Bottom Pose

(C)
Free MD
bottom Binding Pose

(D)
Crystal top
binding Pose
Figure 71. H-bond network in the layers formed by DNA residues in the representative
structure of (A) Crystal Bottom Pose, (B) MD Simulated Crystal Bottom Pose, (C) Bottom
Binding Pose from Free MD Binding Simulations, (D) Crystal top binding Pose, (E) MD
Simulated Crystal top Pose (F) top Binding Pose from Free MD Binding Simulations and
(G) Groove Binding Pose from Free MD Binding Simulations.
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H-bonds

AT-tetrad
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MD Relaxed
Crystal top Pose
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Binding Pose
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Groove Binding Pose
Figure 71 (continued)
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